UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 10-K/A
(Amendment No. 1)
(Mark One)
☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2019
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___to _____
Commission File Number 001-31932
_______________________
CATASYS, INC.
(Exact name of registrant as specified in its charter)
_______________________
Delaware | 88-0464853 |
(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification Number) |
11601 Wilshire Boulevard,2120 Colorado Ave., Suite 1100230
Los Angeles, California 90025Santa Monica, CA 90404
(Address of principal executive offices, including zip code)
(310) 444-4300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:Act:
Title of each className of each exchange on which registered
Common Stock, Par Value $0.0001 Per ShareThe Nasdaq Capital Market
Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||||||
Common Stock, par value $0.0001 per share | CATS | The NASDAQ Stock Exchange |
Securities registered pursuant to Section 12(g) of the Act:Act:
NoneNot Applicable
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
| No ☑ |
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
| No ☑ |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
| No ☐ |
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
| No ☐ |
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of the Form 10-K or any amendment to this Form 10-K. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated filer | Non-accelerated filer ☐ | Smaller reporting company ☑ | ||||||||
Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. . ☑
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
| No ☑ |
As of June 29, 2018,28, 2019, the last business day of the registrant’s second fiscal quarter, the aggregate market value of the common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) was $31,252,254$140,851,867 based on the $6.72$19.22 closing sales price of the common stock on The NASDAQ Capital Market on that date.
As of March 19, 2019,April 24, 2020, there were 16,205,14616,982,992 shares of the registrant’s common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
CATASYS, INC.
Form 10-K Annual Report
For The Fiscal Year Ended December 31, 2018EXPLANATORY NOTE
This Amendment No. 1 (this “Amendment”) on Form 10-K/A amends the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2020 (the “Original 10-K”), to include the information required by Items 10 through 14 of Part III of the Original 10-K. This information was previously omitted from the Original 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by reference to our definitive proxy statement if such statement is filed no later than 120 days after our fiscal year-end.
Items 10 through 14 of Item III in Form 10-K is more limited than what is required to be included in the definitive proxy statement to be filed in connection with our 2020 Annual Meeting of Stockholders. Accordingly, the definitive proxy statement to be filed at a later date will include additional information related to the topics herein and additional information not required by Part III, Items 10 through 14 of Form 10-K.
Pursuant to the SEC rules, Part IV, Item 15 has also been amended to contain the currently dated certificates from the Company’s principal executive and financial officer and principal accounting officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. The certificates of the Company’s principal executive and financial officer and principal accounting officer are attached to this Amendment as Exhibits 31.3 and 31.4. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Additionally, we are not including the certificate under Section 906 of the Sarbanes-Oxley Act of 2002 as no financial statements are being filed with this Amendment.
Except for the information described above, the Company has not modified or updated disclosures provided in the Original 10-K in this Amendment. Accordingly, this Amendment does not reflect events occurring after the filing of the Original 10-K or modify or update those disclosures affected by subsequent events, including any developments relating to the coronavirus (COVID-19) pandemic. Information not affected by this Amendment is unchanged and reflects the disclosures made at the time the Original 10-K was filed.
.
TABLE OF CONTENTS
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART III |
| |
Item 10. | Directors, Executive Officers and Corporate Governance |
|
Item 11. | Executive Compensation |
|
Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|
Item 13. | Certain Relationships and Related Transactions and Director Independence |
|
Item 14. | Principal |
|
PART IV |
| |
Item 15. |
|
|
In this Annual Report on Form 10-K, except as otherwise stated or the context otherwise requires, the terms “the Company,” “our Company,” “we,” “us” or “our” refer to Catasys, Inc., and our wholly owned subsidiaries. Our common stock, par value $0.0001 per share, is referred to as “common stock.”
|
Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed due to factors such as, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry. Additional information concerning factors that could cause or contribute to such differences can be found in the following discussion, as well as in Item 1A. “Risk Factors” and Item 7.“Management’s Discussion and Analysis of Financial Condition and Results of Operations.”We encourage you to read those descriptions carefully. We caution you not to place undue reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law. Such forward-looking statements are not guarantees of future performance and actual results will likely differ, perhaps materially, from those suggested by such forward-looking statements.
ITEM 1. BUSINESS
Overview
We harness proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and cost savings to health plans. We identify, engage and treat health plan members with unaddressed behavioral health conditions that worsen medical comorbidities. Our mission is to help improve the health and save the lives of as many people as possible.
We apply advanced data analytics and predictive modeling to identify members with untreated behavioral health conditions, whether diagnosed or not, and coexisting medical conditions that may be impacted through treatment in the OnTrak program. We then uniquely engage health plan members who do not typically seek behavioral healthcare by leveraging proprietary enrollment capabilities built on deep insights into the drivers of care avoidance. Our technology enabled OnTrak solution is an integrated suite of services that includes evidence-based psychosocial and medical interventions delivered either in-person or via telehealth, nurse-led care coaching and local community support. We believe that the program is currently improving member health and, at the same time, demonstrating reduced medical utilization, driving a reduction in total health plan costs for enrolled members.
We have contracted with leading national and regional health plans to make OnTrak available to eligible members in California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, Nebraska, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.
We believe that our business and operations as outlined above are in substantial compliance with applicable laws and regulations. However, the healthcare industry is highly regulated, and the criteria are often vague and subject to change and interpretation by various federal and state legislatures, courts, enforcement and regulatory authorities. Our future prospects are subject to the legal, regulatory, commercial and scientific risks outlined below and in Item 1.A “Risk Factors.”
Substance Dependence
Scientific research indicates that not only can drugs interfere with normal brain functioning, but they can also have long-lasting effects that persist even after the drug is no longer being used. Data indicates that at some point, changes may occur in the brain that can turn drug and alcohol abuse into substance dependence—a chronic, relapsing, and sometimes fatal disease. Those dependent on drugs may suffer from compulsive drug craving and usage and be unable to stop drug use or remain drug abstinent without effective treatment. Professional medical treatment may be necessary to end this physiologically-based compulsive behavior.
Substance dependence is a worldwide problem with prevalence rates continuing to rise despite the efforts by national and local health authorities to curtail its growth. Substance dependence disorders affect many people and have wide-ranging social consequences. In 2016, an estimated 20.1 million adults in the United States (U.S.) met the criteria for substance dependence, according to the National Survey of Drug Use and Health.
We believe the best results in treating substance dependence can be achieved in programs such as our OnTrak solution that integrate psychosocial and medical treatment modalities and provide longer term support on an out-patient basis.
Anxiety Disorders
According to the National Institute of Mental Health, anxiety disorders are the most common mental illness in the U.S., affecting an estimated 19.1% of adults aged 18 years or older. People with anxiety disorders are:
|
|
|
|
Mood Disorders
In 2016, an estimated 10.3 million U.S. adults aged 18 or older, or approximately 4.3% of all U.S. adults, had at least one major depressive episode in the past year, according to the National Institute of Mental Health. Patients with substance dependence and mood disorders were ranked four out of the top 10 reasons leading to readmission rates for Medicaid patients.
Our Market
The true impact of behavioral health is often under-identified by organizations that provide healthcare benefits. The reality is that individuals with unaddressed behavioral health conditions that worsen chronic medical comorbidities cost health plans and employers a disproportionate amount of money.
When considering behavioral health-related costs, many organizations have historically only looked at direct treatment costs–usually behavioral claims. In fact, for the members we seek to engage our solution, costs associated with behavioral health treatment represent a small portion of their overall healthcare claims, while the medical costs are significant.
According to the U.S. Census Bureau in 2014, there were over 283 million lives in the U.S. covered by various private managed care programs, including Preferred Provider Organizations (PPOs), Health Maintenance Organizations (HMOs), self-insured employers and managed Medicare/Medicaid programs. Each year, based on our analysis, approximately 1.9% of commercial plan members will have a substance dependence diagnosis, and that figure may be lesser or greater for specific payors depending on the health plan demographics and location. A smaller, high-cost subset of this population drives the majority of the claims costs for the overall substance dependent population. For commercial members with substance dependence and a total annual claims cost of at least $7,500, the average annual per member claims cost is $30,000, compared with an average of $3,250 for a commercial non-substance dependent member, according to our research.
Our Customers
Our customers provide health insurance to individuals or groups (Contracted Membership). We contract with our customers to provide our OnTrak solution to the customers’ Contracted Membership generally in specific lines of business (e.g., commercial, Medicare, Medicaid, etc.) and/or specific states or other geographical areas and for specific indications, such as substance use disorders, anxiety and depression. We refer to the Contracted Membership to whom we are providing the OnTrak solution as Covered Lives. Generally, we receive data relating to the Covered Lives on a regular basis from our customers. We use that data to identify members who meet our contractual eligibility requirements (Eligible Members) and we attempt to engage and enroll those members in our OnTrak solution. Our Eligible Members can fluctuate significantly from month to month due to fluctuations in our customers’ Contracted Membership and changes in eligibility due to changes in claims or eligibility data provided to us by our customers. Based on our analysis of the data provided to us by our customers, approximately 2% - 3% of the adult Contracted Membership in a health plan is anticipated to be eligible for our OnTrak solution. There can be no assurance that the data we have analyzed to date will be predictive of the future or that the portion of Covered Lives that are eligible for our programs will not change in the future. In addition, the percentage of Eligible Members in any lines of Covered Lives may fluctuate substantially from period to period.
Our Solution: OnTrak™
Our OnTrak solution includes the identification, engagement and treatment of health plan members with unaddressed behavioral health conditions that worsen medical comorbidities. We specifically focus on members with anxiety, depression and/or substance use disorder(s). We apply claims-based analytics and predictive modeling to first identify health plan members with medical costs that may be impacted through behavioral health treatment with the OnTrak program. These members may or may not be diagnosed with a behavioral condition. We then conduct multichannel outreach to eligible members, which results in an approximate 20% annual enrollment rate. Enrolled members receive nurse-led care coaching, the opportunity to participate in telehealth or face-to-face evidence-based psychosocial and pharmacological treatment and in some cases, in-market Community Care Coordinator support. We believe the benefits of OnTrak include improved clinical outcomes and decreased costs for the payor, as well as improved quality of life for the member. We provide outcomes reporting to payors on a periodic basis to demonstrate the value of the program. Enrolled members achieve an average gross cost reduction of approximately 54% for the year after enrollment compared to the 12 months prior to enrollment.
Our Strategy
Our business strategy is to deliver proven, repeatable clinical and financial outcomes to health plans for their members with unaddressed behavioral conditions that worsen medical comorbidities. We do this by identifying, engaging and treating these members through our OnTrak solution. Our OnTrak solution to date has focused on substance use disorder(s), anxiety and depression.
Key elements of our business strategy include:
|
|
|
|
|
|
|
|
Key elements of our growth strategy include:
|
|
|
|
|
|
|
|
Our Operations
Healthcare Services
Our OnTrak solution combines nurse-led care coaching, innovative psychosocial and medical treatment delivered through a proprietary provider network and in-market support from Community Care Coordinators. The solution is designed to help payors treat and manage populations struggling with substance use disorder(s), depression, and anxiety to improve their health and thereby decrease their overall health care costs.
As of March 19, 2019, we have contracts with nine health plans, two of which have merged and are in the process of integrating operations. We are enrolling patients under all nine of these contracts.
We are currently marketing our OnTrak solution to payors on a case rate, monthly fee, or fee for service basis, which involves educating them on the disproportionately high cost of their population with unaddressed behavioral health conditions that exacerbate medical comorbidities, and demonstrating the potential for OnTrak to reduce these costs.
Competition
Healthcare Services
Our OnTrak solution to date has focused on substance dependence, anxiety and depression, and is marketed to health plans and other insurance payors. While we believe our products and services are unique, we operate in highly competitive markets. We compete with other healthcare management service organizations, care management and disease management companies, including managed behavioral health organizations (MBHOs) that manage behavioral health benefits, perform utilization reviews, provide case management and patient coaching, and pay their network of providers for behavioral health services delivered. Most of these competitors are significantly larger and have greater financial, marketing and other resources than us. We also compete with companies that use data analytics to identify health plan members with behavioral health conditions and either provide coaching and/or therapy or match members with treatment providers. There are also several companies that use digital-only approaches to treating behavioral health conditions. Some of these competitors have secured reimbursement for their products or services from health plans. We believe these organizations are serving a different segment of the market and do not provide an end-to-end integrated solution with financial outcomes. We believe our product is the most comprehensive one to focus exclusively on engaging and treating members whose anxiety, depression, or substance use disorders are exacerbating co-existing medical conditions through our coaches and network of providers using specially designed treatment regimens.
In addition, managed care companies may seek to provide similar specialty healthcare services directly to their members, rather than by contracting with us for such services. Behavioral health conditions, including substance dependence, are typically managed for insurance companies by internal divisions or third-parties (MBHOs) frequently under capitated arrangements. Under such arrangements, MBHOs are paid a fixed monthly fee and must pay providers for provided services, which gives such entities an incentive to decrease cost and utilization of services by members. Our integrated program for members with unaddressed substance dependence, anxiety, and depression increases treatment while reducing the overall health care costs of the members, versus the population utilization management programs that MBHOs offer to manage a health benefit.
We believe that our ability to offer customers an outcomes-based comprehensive and integrated solution, including the utilization of innovative medical and psychosocial treatments and engagement methodologies, and our network of treatment providers, will enable us to compete effectively. However, there can be no assurance that we will not encounter more effective competition in the future, which would limit our ability to maintain or increase our business.
Once we contract with a third-party payor, we implement our program in conjunction with the third-party payor and then commence outreach to eligible members to enroll them in our OnTrak solution. In this enrollment process, we compete against numerous other providers of behavioral health treatment programs, facilities and providers for those members that elect to receive treatment for their behavioral health conditions (see Treatment Programs below). We believe we provide members with a more comprehensive solution, but members may choose to receive care from other providers. To the extent a member selects a different provider that is part of a health plan network of providers, the cost of such treatment may be paid in whole or in part by our health plan customer.
Trademarks
We rely on a combination of trademark, trade secret and copyright laws and contractual restrictions to protect the proprietary aspects of our technology. Our branded trade names on which we rely include the following:
|
| |
|
|
We require that, as a condition of their employment, employees assign to us their interests in inventions, original works of authorship, copyrights and similar intellectual property rights conceived or developed by them during their employment with us.
Financial Information about Segments
We manage and report our operations through one business segment: Healthcare Services. This segment includes the OnTrak solution marketed to health plans and other third party payors.
Employees
As of March 19, 2019, we employed 209 full-time employees. We are not a party to any labor agreements and none of our employees are represented by a labor union.
Corporate Information
We were incorporated in the State of Delaware on September 29, 2003. Our principal executive offices are located at 11601 Wilshire Blvd, Suite 1100, Los Angeles, California 90025, and our telephone number is (310) 444-4300.
Our corporate website address is www.catasys.com, the contents of which are not incorporated herein. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission. The Securities and Exchange Commission maintains an internet site that contains our public filings with the Securities and Exchange Commission and other information regarding our company, at www.sec.gov. The contents of these websites are not incorporated into this Annual Report. Further, our references to the URLs for these websites are intended to be inactive textual reference only.
ITEM 1A. RISK FACTORS
You should carefully consider and evaluate all of the information in this report, including the risk factors listed below. Risks and uncertainties in addition to those we describe below, that may not be presently known to us, or that we currently believe are immaterial, may also harm our business and operating results and financial condition, as well as adversely affect the value of an investment in our Company. If any of these risks occur, our business, results of operations and financial condition could be harmed, the price of our common stock could decline, and future events and circumstances could differ significantly from those anticipated in the forward-looking statements contained in this Annual Report on Form 10-K.
Risks related to our business
We have a limited operating history, expect to continue to incur substantial operating losses and may be unable to obtain additional financing.
We have been unprofitable since our inception in 2003 and expect to incur substantial additional operating losses and negative cash flow from operations for at least the next twelve months. At December 31, 2018, cash, cash equivalents and restricted cash was approximately $3.6 million and accumulated deficit was approximately $306 million. During the year ended December 31, 2018, our cash and cash equivalents used by operating activities was $8.6 million. Additionally, we had negative working capital of $2.2 million. We expect our current cash resources to cover expenses through at least the next twelve months, however, delays in cash collections, revenue, or unforeseen expenditures could impact this estimate.
Historically, we have seen and continue to see net losses, net loss from operations, negative cash flow from operating activities, and historical working capital deficits as we continue through a period of rapid growth. The accompanying financial statements do not reflect any adjustments that might result if we were unable to continue as a going concern. We have alleviated substantial doubt by both entering into contracts for additional revenue-generating health plan customers and expanding our OnTrak program within existing health plan customers. To support this increased demand for services, we invested and will continue to invest in additional headcount needed to support the anticipated growth. Additional management plans include increasing the outreach pool as well as improving our current enrollment rate. We will continue to explore ways to increase margins on both existing and new members.
We have a growing customer base and believe we are able to fully scale our operations to service the contracts and future enrollment providing leverage in these investments that will generate positive cash flow by the end of 2019. We believe we will have enough capital to cover expenses through the foreseeable future and we will continue to monitor liquidity. If we add more health plans than budgeted, increase the size of the outreach pool by more than we anticipate, decide to invest in new products or seek out additional growth opportunities, we would consider financing these options with either a debt or equity financing.
The terms of our venture loan and security agreement place restrictions on our operating and financial flexibility, and failure to comply with covenants or to satisfy certain conditions of the agreement may result in acceleration of our repayment obligations, which could significantly harm our liquidity, financial condition, operating results, business and prospects and cause the price of our securities to decline.
In 2018, we entered into (i) a venture loan and security agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”), which provides for $7.5 million in loans to the borrowers named therein, including initial loans in the amount of $5.0 million and an additional $2.5 million loan funded upon our achievement of trailing three month billings exceeding $5 million, and (ii) a loan and security agreement in connection with a $2.5 million receivables financing facility (the “Facility Agreement,” and together with the Loan Agreement, the “Debt Financing Agreements”) with Corporate Finance, a division of Heritage Bank of Commerce (“Heritage”). Our obligations under the Debt Financing Agreements are secured by a first priority security interest in all of our personal property, with the exception of intellectual property, and Heritage’s rights in collateral securing the Facility Agreement are senior to Horizon’s rights in collateral securing the Loan Agreement pursuant to an intercreditor agreement.
The Loan Agreement provides for customary affirmative and restrictive covenants, including a limit on our outstanding indebtedness and a requirement that our aggregate billings for any two quarter period be greater than our billings in the preceding two quarter period but excluding any covenants to attain or maintain other financial metrics, and also includes customary events of default and following any applicable cure periods, including for payment failures, breaches of covenants, change of control and material adverse changes. The Facility Agreement includes customary affirmative and restrictive covenants, including covenants to maintain an asset coverage ratio of at least 2.00 to 1.00 (subject to decrease to 1.25 to 1.00 in the event the Company is EBITDA positive for at least two quarters), that the Company’s EBITDA for any quarter shall not negatively vary by more than 30% from the Company’s financial plan and that the Borrowers’ liquidity shall be at least three times the absolute value of the Company’s EBITDA loss for the preceding three months, and also includes customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes. The Debt Financing Agreements also include customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes. Upon the occurrence of an event of default under either Debt Financing Agreement, a default interest rate of an additional 5% may be applied to the outstanding loan balances, certain minimum revenue based payment guarantees become due and the relevant lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth therein.
In March 2019, we entered into an amended and restated venture loan and security agreement (as so amended and restated, the “Amended Loan Agreement”) with Horizon, which provides for up to $15.0 million in loans to us, including initial term loans in the amount of $7.5 million previously funded under the original Loan Agreement entered into in June 2018 and an additional up to $7.5 million loan in three revolving tranches of $2.5 million in availability, subject to the Company’s achievement of trailing three month billings exceeding $5.0 million, $7.0 million and $8.0 million, respectively. An initial advance of $2.5 million was funded upon the execution and delivery of the Loan Agreement, subject to repayment if the foregoing $5.0 million threshold is not reached by July 1, 2019. We concurrently entered into an amendment to the previously disclosed $2.5 million A/R Facility with Corporate Finance intended primarily to reflect the amendment and restatement of the Amended Loan Agreement.
As of March 19, 2019 there was $10.0 million outstanding under the Loan Agreement and no amount outstanding under the Facility Agreement, respectively.
Our failure to meet our obligations under the Debt Financing Agreements and any declaration by Horizon or Heritage of an event of default thereunder could significantly harm our liquidity, financial condition, operating results, business, and prospects and cause the price of our securities to decline.
We may need additional funding, and we cannot guarantee that we will find adequate sources of capital in the future.
We have incurred negative cash flows from operations since inception and have expended, and expect to continue to expend, substantial funds to grow our business. We may require additional funds before we achieve positive cash flows and we may never become cash flow positive.
If we raise additional funds by issuing equity securities, such financing will result in further dilution to our stockholders. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of holders of our common stock, and the terms of the debt securities issued could impose significant restrictions on our operations in addition to those referenced above.
We do not know whether additional financing will be available on commercially acceptable terms, or at all. If adequate funds are not available or are not available on commercially acceptable terms, we may need to continue to downsize, curtail program development efforts or halt our operations altogether.
We may fail to successfully manage and grow our business, which could adversely affect our results of operations, financial condition and business.
Continued expansion could put significant strain on our management, operational and financial resources. The need to comply with the rules and regulations of the SEC will continue to place significant demands on our financial and accounting staff, financial, accounting and information systems, and our internal controls and procedures, any of which may not be adequate to support our anticipated growth. The need to comply with the state and federal healthcare, security and privacy regulation will continue to place significant demands on our staff and our policies and procedures, any of which may not be adequate to support our anticipated growth. We may not be able to effectively hire, train, retain, motivate and manage required personnel. Our failure to manage growth effectively could limit our ability to satisfy our reporting obligations, or achieve our marketing, commercialization and financial goals.
We may be unable to successfully execute on our growth initiatives, business strategies or operating plans.
We are continually executing a number of growth initiatives, strategies and operating plans designed to enhance our business. The anticipated benefits from these efforts are based on several assumptions that may prove to be inaccurate. Moreover, we may not be able to successfully complete these growth initiatives, strategies and operating plans and realize all of the benefits, including growth targets and cost savings, that we expect to achieve or it may be more costly to do so than we anticipate. A variety of risks could cause us not to realize some or all of the expected benefits. These risks include, among others, delays in the anticipated timing of activities related to such growth initiatives, strategies and operating plans, increased difficulty and cost in implementing these efforts, including difficulties in complying with new regulatory requirements and the incurrence of other unexpected costs associated with operating the business. Moreover, our continued implementation of these programs may disrupt our operations and performance. As a result, we cannot assure you that we will realize these benefits. If, for any reason, the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies and operating plans adversely affect our operations or cost more or take longer to effectuate than we expect, or if our assumptions prove inaccurate, our business, financial condition and results of operations may be materially adversely affected.
Our programs may not be as effective as we believe them to be, which could limit our potential revenue growth.
Our belief in the efficacy of our OnTrak solution is based on a limited experience with a relatively small number of patients. Such results may not be statistically significant, have not been subjected to close scientific scrutiny, and may not be indicative of the long-term future performance of treatment with our programs. If the initially indicated results cannot be successfully replicated or maintained over time, utilization of our programs could decline substantially. There are no standardized methods for measuring efficacy of programs such as ours. Even if we believe our solutions are effective, our customers could determine they are not utilizing different outcomes measures. In addition, even if our customers determine our solutions are effective they may discontinue them because they determine that the aggregate cost savings are not sufficient or that our programs do not have a high enough return on investment. Our success is dependent on our ability to enroll third-party payor members in our OnTrak solutions. Large scale outreach and enrollment efforts have not been conducted and only for limited time periods and we may not be able to achieve the anticipated enrollment rates.
Our OnTraksolution may not become widely accepted, which could limit our growth.
Our ability to achieve further marketplace acceptance for our OnTrak solution is dependent on our ability to demonstrate financial and clinical outcomes from our agreements. If we are unable to secure sufficient contracts to achieve recognition or acceptance of our OnTrak solution or if our program does not demonstrate the expected level of clinical improvement and cost savings, it is unlikely that we will be able to achieve widespread market acceptance.
Disappointing results for our solutions or failure to attain our publicly disclosed milestones could adversely affect market acceptance and have a material adverse effect on our stock price.
Disappointing results, later-than-expected press release announcements or termination of evaluations, pilot programs or commercial OnTrak solutions could have a material adverse effect on the commercial acceptance of our solutions, our stock price and on our results of operations. In addition, announcements regarding results, or anticipation of results, may increase volatility in our stock price. In addition to numerous upcoming milestones, from time to time we provide financial guidance and other forecasts to the market. While we believe that the assumptions underlying projections and forecasts we make publicly available are reasonable, projections and forecasts are inherently subject to numerous risks and uncertainties. Any failure to achieve milestones, or to do so in a timely manner, or to achieve publicly announced guidance and forecasts, could have a material adverse effect on our results of operations and the price of our common stock.
Our industry is highly competitive, and we may not be able to compete successfully.
The healthcare business in general, and the behavioral health treatment business in particular, are highly competitive. While we believe our products and services are unique, we operate in highly competitive markets. We compete with other healthcare management service organizations, care management and disease management companies, including Managed Behavioral Healthcare Organizations (MBHOs), other specialty healthcare and managed care companies, and healthcare technology companies that are offering treatment and support of behavioral health on-line and on mobile devices. Most of our competitors are significantly larger and have greater financial, marketing and other resources than us. We believe that our ability to offer customers a comprehensive and integrated behavioral health solution, including the utilization of our analytical models and innovative member engagement methodologies, will enable us to compete effectively. However, there can be no assurance that we will not encounter more effective competition in the future, that we will have financial resources to continue to improve our offerings or that we will be successful improving them, which would limit our ability to maintain or increase our business.
Our competitors may develop and introduce new processes and products that are equal or superior to our programs in treating behavioral health conditions. Accordingly, we may be adversely affected by any new processes and products developed by our competitors.
A substantial percentage of our revenues are attributable to four large customers, any or all of which may terminate our services at any time.
Four customers account for an aggregate of 76% and 90% of our revenue in 2018 and 2017, respectively, and four customers represented an aggregate of 88% and 96% of our accounts receivable as of December 31, 2018 and 2017, respectively. We expect that revenues from a limited number of customers will continue for the foreseeable future. Sales to these customers are made pursuant to agreements with flexible termination provisions, generally entitling the customer to terminate with or without cause on limited notice to us. We may not be able to keep our key customers, or these customers may decrease their enrollment levels. Any substantial decrease or delay in revenues relating to one or more of our key customers would harm our financial results. If revenues relating to current key customers cease or are reduced, we may not obtain sufficient enrollments from other customers necessary to offset any such losses or reductions.
We depend on key personnel, the loss of which could impact the ability to manage our business.
We are highly dependent on our senior management and key operating and technical personnel. The loss of the services of any member of our senior management and key operating and technical personnel could have a material adverse effect on our business, operating results and financial condition. We also rely on consultants and advisors to assist us in formulating our strategy.
We will need to hire additional employees in order to achieve our objectives. There is currently intense competition for skilled executives and employees with relevant expertise, and this competition is likely to continue. The inability to attract and retain sufficient personnel could adversely affect our business, operating results and financial condition.
Our success depends largely upon the continued services of our key executive officers. These executive officers are at‑will employees and therefore they may terminate employment with us at any time with no advance notice. We also rely on our leadership team in the areas of research and development, marketing, services and general and administrative functions. From time to time, there may be changes in our executive management team resulting from the hiring or departure of executives, which could disrupt our business. The replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.
To continue to execute our growth strategy, we also must attract and retain highly skilled personnel. Competition is intense for qualified professionals. We may not be successful in continuing to attract and retain qualified personnel. We have from time to time in the past experienced, and we expect to continue to experience in the future, difficulty in hiring and retaining highly skilled personnel with appropriate qualifications. The pool of qualified personnel with experience working in the healthcare market is limited overall. In addition, many of the companies with which we compete for experienced personnel have greater resources than we have.
In addition, in making employment decisions, particularly in high‑technology industries, job candidates often consider the value of the stock options or other equity instruments they are to receive in connection with their employment. Volatility in the price of our stock may, therefore, adversely affect our ability to attract or retain highly skilled personnel. Further, the requirement to expense stock options and other equity instruments may discourage us from granting the size or type of stock option or equity awards that job candidates require to join our company. Failure to attract new personnel or failure to retain and motivate our current personnel, could have a material adverse effect on our business, financial condition and results of operations.
We are dependent on our ability to recruit, retain and develop a very large and diverse workforce. We must transform our culture in order to successfully grow our business.
Our products and services and our operations require a large number of employees. A significant number of employees have joined us in recent years as we continue to grow and expand our business. Our success is dependent on our ability to transform our culture, align our talent with our business needs, engage our employees and inspire our employees to be open to change, to innovate and to maintain member- and client-focus when delivering our services. Our business would be adversely affected if we fail to adequately plan for succession of our executives and senior management; or if we fail to effectively recruit, integrate, retain and develop key talent and/or align our talent with our business needs, in light of the current rapidly changing environment. While we have succession plans in place and we have employment arrangements with a limited number of key executives, these do not guarantee that the services of these or suitable successor executives will continue to be available to us.
We may be subject to future litigation, which could result in substantial liabilities that may exceed our insurance coverage.
All significant medical treatments and procedures, including treatment utilizing our programs, involve the risk of serious injury or death. While we have not been the subject of any such claims, our business entails an inherent risk of claims for personal injuries and substantial damage awards. We cannot control whether individual physicians and therapists will apply the appropriate standard of care in determining how to treat their patients. While our agreements typically require physicians to indemnify us for their negligence, there can be no assurance they will be willing and financially able to do so if claims are made. In addition, our license agreements require us to indemnify physicians, hospitals or their affiliates for losses resulting from our negligence.
We currently have insurance coverage for personal injury claims, directors’ and officers’ liability insurance coverage, and errors and omissions insurance. We may not be able to maintain adequate liability insurance at acceptable costs or on favorable terms. We expect that liability insurance will be more difficult to obtain and that premiums will increase over time and as the volume of patients treated with our programs increases. In the event of litigation, we may sustain significant damages or settlement expense (regardless of a claim's merit), litigation expense and significant harm to our reputation.
If third-party payors fail to provide coverage and adequate payment rates for our solutions, our revenue and prospects for profitability will be harmed.
Our future revenue growth will depend in part upon our ability to contract with health plans and other insurance payors for our OnTrak solutions. In addition, insurance payors are increasingly attempting to contain healthcare costs, and may not cover or provide adequate payment for our programs. Adequate insurance reimbursement might not be available to enable us to realize an appropriate return on investment in research and product development, and the lack of such reimbursement could have a material adverse effect on our operations and could adversely affect our revenues and earnings.
We may not be able to achieve promised savings for our OnTrak contracts, which could result in pricing levels insufficient to cover our costs or ensure profitability.
Many of our OnTrak contracts are based upon anticipated or guaranteed levels of savings for our customers and achieving other operational metrics resulting in incentive fees based on savings. If we are unable to meet or exceed promised savings, achieve agreed upon operational metrics, or favorably resolve contract billing and interpretation issues with our customers, we may be required to refund from the amount of fees paid to us any difference between savings that were guaranteed and the savings, if any, which were actually achieved; or we may fail to earn incentive fees based on savings. Accordingly, during or at the end of the contract terms, we may be required to refund some or all of the fees paid for our services. This exposes us to significant risk that contracts negotiated and entered into may ultimately be unprofitable. In addition, managed care operations are at risk for costs incurred to provide agreed upon services under our solution. Therefore, failure to anticipate or control costs could have a materially adverse effect on our business.
Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
As of December 31, 2018, we had net operating loss carryforwards (NOLs) of approximately $260 million for federal income tax purposes that will begin to expire in 2023. These NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce or eliminate our future federal income taxes otherwise payable. Section 382 of the Internal Revenue Code imposes limitations on a corporation's ability to utilize NOLs if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. In the event that an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate as defined in the Internal Revenue Code. Any unused annual limitation may be carried over to later years. We may be found to have experienced an ownership change under Section 382 as a result of events in the past or the issuance of shares of common stock, or a combination thereof. If so, the use of our NOLs, or a portion thereof, against our future taxable income may be subject to an annual limitation under Section 382, which may result in expiration of a portion of our NOLs before utilization.
Risks related to our intellectual property
Confidentiality agreements with employees, treating physiciansand others may not adequately prevent disclosure of trade secrets and other proprietary information.
In order to protect our proprietary technology and processes, we rely in part on confidentiality provisions in our agreements with employees, treating physicians, and others. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
We may be subject to claims that we infringe the intellectual property rights of others, and unfavorable outcomes could harm our business.
Our future operations may be subject to claims, and potential litigation, arising from our alleged infringement of patents, trade secrets, trademarks or copyrights owned by other third parties. Within the healthcare, drug and bio-technology industry, many companies actively pursue infringement claims and litigation, which makes the entry of competitive products more difficult. We may experience claims or litigation initiated by existing, better-funded competitors and by other third parties. Court-ordered injunctions may prevent us from continuing to market existing products or from bringing new products to market and the outcome of litigation and any resulting loss of revenues and expenses of litigation may substantially affect our ability to meet our expenses and continue operations.
Risks related to our healthcare industry
Recent changes in insurance and health care laws have created uncertainty in the health care industry.
The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010, generally known as the Health Care Reform Law, significantly expanded health insurance coverage to uninsured Americans and changed the way health care is financed by both governmental and private payers. Following the 2016 federal elections, which resulted in the election of the Republican presidential nominee and Republican majorities in both houses of Congress, there were renewed legislative efforts to significantly modify or repeal the Health Care Reform Law and certain executive policy changes designed to modify its impact, including the enactment of the Tax Cuts and Jobs Act in December 2017 which repealed the penalties under the Health Care Reform Law for uninsured persons. We cannot predict what further reform proposals, if any, will be adopted, when they may be adopted, or what impact they may have on our business. There may also be other risks and uncertainties associated with the Health Care Reform Law. If we fail to comply or are unable to effectively manage such risks and uncertainties, our financial condition and results of operations could be adversely affected.
Our policies and procedures may not fully comply with complex and increasing regulation by state and federal authorities, which could negatively impact our business operations.
The healthcare industry is highly regulated and continues to undergo significant changes as third-party payors, such as Medicare and Medicaid, traditional indemnity insurers, managed care organizations and other private payors, increase efforts to control cost, utilization and delivery of healthcare services. Healthcare companies are subject to extensive and complex federal, state and local laws, regulations and judicial decisions. Our failure or the failure of our treating physicians, to comply with applicable healthcare laws and regulations may result in the imposition of civil or criminal sanctions that we cannot afford, or require redesign or withdrawal of our programs from the market.
We may become subject to medical liability claims, which could cause us to incur significant expenses and may require us to pay significant damages if not covered by insurance.
Our business entails the risk of medical liability claims against both our providers and us. Although we carry insurance covering medical malpractice claims in amounts that we believe are appropriate in light of the risks attendant to our business, successful medical liability claims could result in substantial damage awards that exceed the limits of our insurance coverage. We carry professional liability insurance for ourselves, and we separately carry a general insurance policy, which covers medical malpractice claims. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our services. As a result, adequate professional liability insurance may not be available to us in the future at acceptable costs or at all.
Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us and divert the attention of our management and our providers from our operations, which could have a material adverse effect on our business, financial condition and results of operations. In addition, any claims may adversely affect our business or reputation.
Our business practices may be found to constitute illegal fee-splitting or corporate practice of medicine, which may lead to penalties and adversely affect our business.
Many states, including California where our principal executive offices are located, have laws that prohibit business corporations, such as us, from practicing medicine, exercising control over medical judgments or decisions of physicians or other health care professionals (such as nurses or nurse practitioners), or engaging in certain business arrangements with physicians or other health care professionals, such as employment of physicians and other health care professionals or fee-splitting. The state laws and regulations and administrative and judicial decisions that enumerate the specific corporate practice and fee-splitting rules vary considerably from state to state and are enforced by both the courts and government agencies, each with broad discretion. Courts, government agencies or other parties, including physicians, may assert that we are engaged in the unlawful corporate practice of medicine, fee-splitting, or payment for referrals by providing administrative and other services in connection with our treatment programs. As a result of such allegations, we could be subject to civil and criminal penalties, our contracts could be found invalid and unenforceable, in whole or in part, or we could be required to restructure our contractual arrangements. If so, we may be unable to restructure our contractual arrangements on favorable terms, which would adversely affect our business and operations.
Our business practices may be found to violate anti-kickback, physician self-referral or false claims laws, which may lead to penalties and adversely affect our business.
The healthcare industry is subject to extensive federal and state regulation with respect to kickbacks, physician self-referral arrangements, false claims and other fraud and abuse issues.
The federal anti-kickback law (the “Anti-Kickback Law”) prohibits, among other things, knowingly and willfully offering, paying, soliciting, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program. “Remuneration” is broadly defined to include anything of value, such as, for example, cash payments, gifts or gift certificates, discounts, or the furnishing of services, supplies, or equipment. The Anti-Kickback Law is broad, and it prohibits many arrangements and practices that are lawful in businesses outside of the health care industry.
Recognizing the breadth of the Anti-Kickback Law and the fact that it may technically prohibit many innocuous or beneficial arrangements within the health care industry, the Office of Inspector General (“OIG”) has issued a series of regulations, known as the “safe harbors.” Compliance with all requirements of a safe harbor immunizes the parties to the business arrangement from prosecution under the Anti-Kickback Law. The failure of a business arrangement to fit within a safe harbor does not necessarily mean that the arrangement is illegal or that the OIG will pursue prosecution. Still, in the absence of an applicable safe harbor, a violation of the Anti-Kickback Law may occur even if only one purpose of an arrangement is to induce referrals. The penalties for violating the Anti-Kickback Law can be severe. These sanctions include criminal and civil penalties, imprisonment, and possible exclusion from the federal health care programs. Many states have adopted laws similar to the Anti-Kickback Law, and some apply to items and services reimbursable by any payor, including private insurers.
In addition, the federal ban on physician self-referrals, commonly known as the Stark Law, prohibits, subject to certain exceptions, physician referrals of Medicare patients to an entity providing certain “designated health services” if the physician or an immediate family member of the physician has any financial relationship with the entity. A “financial relationship” is created by an investment interest or a compensation arrangement. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties, and possible exclusion from the federal health care programs. In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor.
The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government. Under the False Claims Act, a person acts knowingly if he has actual knowledge of the information or acts in deliberate ignorance or in reckless disregard of the truth or falsity of the information. Specific intent to defraud is not required. Violations of other laws, such as the Anti-Kickback Law or the FDA prohibitions against promotion of off-label uses of drugs, can lead to liability under the federal False Claims Act. The qui tam provisions of the False Claims Act allow a private individual to bring an action on behalf of the federal government and to share in any amounts paid by the defendant to the government in connection with the action. The number of filings of qui tam actions has increased significantly in recent years. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties of between $5,500 and $11,000 for each false claim. Conduct that violates the False Claims Act may also lead to exclusion from the federal health care programs. Given the number of claims likely to be at issue, potential damages under the False Claims Act for even a single inappropriate billing arrangement could be significant. In addition, various states have enacted similar laws modeled after the False Claims Act that apply to items and services reimbursed under Medicaid and other state health care programs, and, in several states, such laws apply to claims submitted to all payors.
On May 20, 2009, the Federal Enforcement and Recovery Act of 2009, or FERA, became law, and it significantly amended the federal False Claims Act. Among other things, FERA eliminated the requirement that a claim must be presented to the federal government. As a result, False Claims Act liability extends to any false or fraudulent claim for government money, regardless of whether the claim is submitted to the government directly, or whether the government has physical custody of the money. FERA also specifically imposed False Claims Act liability if an entity “knowingly and improperly avoids or decreases an obligation to pay or transmit money or property to the Government.” As a result, the knowing and improper failure to return an overpayment can serve as the basis for a False Claims Act action. In March 2010, Congress passed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, which also made sweeping changes to the federal False Claims Act. The ACA also established that Medicare and Medicaid overpayments must be reported and returned within 60 days of identification or when any corresponding cost report is due.
Finally, the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations created the crimes of health care fraud and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including a private insurer. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for health care benefits, items, or services. A violation of this statute is a felony and may result in fines, imprisonment, or exclusion from the federal health care programs.
Federal or state authorities may claim that our fee arrangements, our agreements and relationships with contractors, hospitals and physicians, or other activities violate fraud and abuse laws and regulations. If our business practices are found to violate any of these laws or regulations, we may be unable to continue with our relationships or implement our business plans, which would have an adverse effect on our business and results of operations. Further, defending our business practices could be time consuming and expensive, and an adverse finding could result in substantial penalties or require us to restructure our operations, which we may not be able to do successfully.
Our business practices may be subject to state regulatory and licensure requirements.
Our business practices may be regulated by state regulatory agencies that generally have discretion to issue regulations and interpret and enforce laws and rules. These regulations can vary significantly from jurisdiction to jurisdiction, and the interpretation of existing laws and rules also may change periodically. Some of our business and related activities may be subject to state health care-related regulations and requirements, including managed health care, utilization review (UR) or third-party administrator-related regulations and licensure requirements. These regulations differ from state to state, and may contain network, contracting, and financial and reporting requirements, as well as specific standards for delivery of services, payment of claims, and adequacy of health care professional networks. If a determination is made that we have failed to comply with any applicable state laws or regulations, our business, financial condition and results of operations could be adversely affected.
If our providers or experts are characterized as employees, we would be subject to employment and withholding liabilities.
We structure our relationships with our providers and experts in a manner that we believe results in an independent contractor relationship, not an employee relationship. An independent contractor is generally distinguished from an employee by his or her degree of autonomy and independence in providing services. A high degree of autonomy and independence is generally indicative of a contractor relationship, while a high degree of control is generally indicative of an employment relationship. Although we believe that our providers and experts are properly characterized as independent contractors, tax or other regulatory authorities may in the future challenge our characterization of these relationships. If such regulatory authorities or state, federal or foreign courts were to determine that our providers or experts are employees, and not independent contractors, we would be required to withhold income taxes, to withhold and pay social security, Medicare and similar taxes and to pay unemployment and other related payroll taxes. We would also be liable for unpaid past taxes and subject to penalties. As a result, any determination that our providers or experts are our employees could have a material adverse effect on our business, financial condition and results of operations.
We may be subject to healthcare anti-fraud initiatives, which may lead to penalties and adversely affect our business.
State and federal government agencies are devoting increased attention and resources to anti-fraud initiatives against healthcare providers and the entities and individuals with whom they do business, and such agencies may define fraud expansively to include our business practices, including the receipt of fees in connection with a healthcare business that is found to violate any of the complex regulations described above. While to our knowledge we have not been the subject of any anti-fraud investigations, if such a claim were made, defending our business practices could be time consuming and expensive and an adverse finding could result in substantial penalties or require us to restructure our operations, which we may not be able to do successfully.
Our use and disclosure of patient information is subject to privacy and security regulations, which may result in increased costs.
In providing administrative services to healthcare providers and operating our treatment programs, we may collect, use, disclose, maintain and transmit patient information in ways that will be subject to many of the numerous state, federal and international laws and regulations governing the collection, use, disclosure, storage, privacy and security of patient-identifiable health information, including the administrative simplification requirements of the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (HIPAA) and the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). The HIPAA Privacy Rule restricts the use and disclosure of patient information (“Protected Health Information” or “PHI”), and requires safeguarding that information. The HIPAA Security Rule and HITECH establish elaborate requirements for safeguarding PHI transmitted or stored electronically. HIPAA applies to covered entities, which may include healthcare facilities and also includes health plans that will contract for the use of our programs and our services. HIPAA and HITECH require covered entities to bind contractors that use or disclose protected health information (or “Business Associates”) to compliance with certain aspects of the HIPAA Privacy Rule and all of the HIPAA Security Rule. In addition to contractual liability, Business Associates are also directly subject to regulation by the federal government. Direct liability means that we are subject to audit, investigation and enforcement by federal authorities. HITECH imposes new breach notification obligations requiring us to report breaches of “Unsecured Protected Health Information” or PHI that has not been encrypted or destroyed in accordance with federal standards. Business Associates must report such breaches so that their covered entity customers may in turn notify all affected patients, the federal government, and in some cases, local or national media outlets. We may be required to indemnify our covered entity customers for costs associated with breach notification and the mitigation of harm resulting from breaches that we cause. If we are providing management services that include electronic billing on behalf of a physician practice or facility that is a covered entity, we may be required to conduct those electronic transactions in accordance with the HIPAA regulations governing the form and format of those transactions. Services provided under our OnTrak solution not only require us to comply with HIPAA and HITECH but also Title 42 Part 2 of the Code of Federal Regulations (“Part 2”). Part 2 is a federal, criminal law that severely restricts our ability to use and disclose drug and alcohol treatment information obtained from federally-supported treatment facilities. Our operations must be carefully structured to avoid liability under this law. Our OnTrak solution qualifies as a federally funded treatment facility which requires us to disclose information on members only in compliance with Title 42. In addition to the federal privacy regulations, there are a number of state laws governing the privacy and security of health and personal information. The penalties for violation of these laws vary widely and the area is rapidly evolving. We believe that we have taken the steps required of us to comply with health information privacy and security laws and regulations in all jurisdictions, both state and federal. However, we may not be able to maintain compliance in all jurisdictions where we do business. Failure to maintain compliance, or changes in state or federal privacy and security laws could result in civil and/or criminal penalties and could have a material adverse effect on our business, including significant reputational damage associated with a breach. If regulations change or it is determined that we are not in compliance with privacy regulations we may be required to modify aspects of our program which may adversely affect program results and our business or profitability. Under HITECH, we are subject to prosecution or administrative enforcement and increased civil and criminal penalties for non-compliance, including a new, four-tiered system of monetary penalties. We are also subject to enforcement by state attorneys general who were given authority to enforce HIPAA under HITECH.
Certain of our professional healthcare employees, such as nurses, must comply with individual licensing requirements.
All of our healthcare professionals who are subject to licensing requirements, such as our care coaches, are licensed in the state in which they provide professional services in person. While we believe our nurses provide coaching and not professional services, one or more states may require our healthcare professionals to obtain licensure if providing services telephonically across state lines to the state’s residents. Healthcare professionals who fail to comply with these licensure requirements could face fines or other penalties for practicing without a license, and we could be required to pay those fines on behalf of our healthcare professionals. If we are required to obtain licenses for our nurses in states where they provide telephonic coaching, it would significantly increase the cost of providing our product. In addition, new and evolving agency interpretations, federal or state legislation or regulations, or judicial decisions could lead to the implementation of out-of-state licensure requirements in additional states, and such changes would increase the cost of services and could have a material effect on our business.
Security breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.
In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing an off-site co-location facility. These applications and data encompass a wide variety of business critical information including research and development information, commercial information and business and financial information.
The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, viruses, breaches or interruptions due to employee error or malfeasance, terrorist attacks, earthquakes, fire, flood, other natural disasters, power loss, computer systems failure, data network failure, Internet failure or lapses in compliance with privacy and security mandates. Any such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as HIPAA, government enforcement actions and regulatory penalties. We may also be required to indemnify our customers for costs associated with having their data on our system breached. Unauthorized access, loss or dissemination could also interrupt our operations, including our ability to bill our customers, provide customer support services, conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business and damage our reputation, or we may lose one or more of our customers, especially if they felt their data may be breached, any of which could adversely affect our business.
Risks related to our common stock
Our common stock has limited trading volume, and it is therefore susceptible to highprice volatility.
Our common stock is quoted on the NASDAQ Capital Market under the symbol “CATS” and has limited trading volume. As such, our common stock is more susceptible to significant and sudden price changes than stocks that are widely followed by the investment community and actively traded on an exchange. The liquidity of our common stock depends upon the presence in the marketplace of willing buyers and sellers. We cannot assure you that you will be able to find a buyer for your shares. We could also subsequently fail to satisfy the standards for continued NASDAQ listing, such as standards having to do with a minimum share price, the minimum number of public shareholders or the aggregate market value of publicly held shares. Any holder of our securities should regard them as a long-term investment and should be prepared to bear the economic risk of an investment in our securities for an indefinite period.
Failure to maintain effective internal controls could adversely affect our operating results and the market for our common stock.
Section 404 of the Sarbanes-Oxley Act of 2002 requires that we maintain internal control over financial reporting that meets applicable standards. As with many smaller companies with small staff, material weaknesses in our financial controls and procedures may be discovered. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction and adversely affect our ability to raise capital.
Approximately 60% of our outstanding common stock is beneficially owned by our chairman and chief executive officer, who has the ability to substantially influence the election of directors and other matters submitted to stockholders.
10,467,380 shares are beneficially held of record by Acuitas Group Holdings, LLC (“Acuitas”), whose sole managing member is our Chairman and Chief Executive Officer, which represents beneficial ownership of approximately 60% of our outstanding shares of common stock. As a result, he has and is expected to continue to have the ability to significantly influence the election of our Board of Directors and the outcome of all other matters submitted to our stockholders. His interest may not always coincide with our interests or the interests of other stockholders, and he may act in a manner that advances his best interests and not necessarily those of other stockholders. One consequence to this substantial influence or control is that it may be difficult for investors to remove management of our Company. It could also deter unsolicited takeovers, including transactions in which stockholders might otherwise receive a premium for their shares over then current market prices.
Our stock price may be subject to substantial volatility, and the value of our stockholders' investment may decline.
The price at which our common stock will trade may fluctuate as a result of a number of factors, including the number of shares available for sale in the market, quarterly variations in our operating results and actual or anticipated announcements of our OnTrak solution, announcements regarding new or discontinued OnTrak solution contracts, new products or services by us or competitors, regulatory investigations or determinations, acquisitions or strategic alliances by us or our competitors, recruitment or departures of key personnel, the gain or loss of significant customers, changes in the estimates of our operating performance, actual or threatened litigation, market conditions in our industry and the economy as a whole.
Numerous factors, including many over which we have no control, may have a significant impact on the market price of our common stock, including:
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
|
Furthermore, stockholders may initiate securities class action lawsuits if the market price of our stock drops significantly, which may cause us to incur substantial costs and could divert the time and attention of our management.
Future sales of common stock by existing stockholders, or the perception that such sales may occur, could depress our stock price.
The market price of our common stock could decline as a result of sales by, or the perceived possibility of sales by, our existing stockholders. We have completed a number of private placements of our common stock and other securities over the last several years, and we have effective resale registration statements pursuant to which the purchasers can freely resell their shares into the market. In addition, most of our outstanding shares are eligible for public resale pursuant to Rule 144 under the Securities Act of 1933, as amended. As of March 19, 2019, approximately 9.2 million shares of our common stock are held by our affiliates and may be sold pursuant to an effective registration statement or in accordance with the volume and other limitations of Rule 144 or pursuant to other exempt transactions. Future sales of common stock by significant stockholders, including those who acquired their shares in private placements or who are affiliates, or the perception that such sales may occur, could depress the price of our common stock.
Future issuances of common stock and hedging activities may depress the trading price of our common stock.
Any future issuance of equity securities, including the issuance of shares upon direct registration, upon satisfaction of our obligations, compensation of vendors, exercise of outstanding warrants, or effectuation of a reverse stock split, could dilute the interests of our existing stockholders, and could substantially decrease the trading price of our common stock. As of March 19, 2019, we have outstanding options to purchase approximately 4,341,116 shares of our common stock and warrants to purchase approximately 1,584,829 shares of our common stock at prices ranging from $1.80 to $1,161.60 per share. We may issue equity securities in the future for a number of reasons, including to finance our operations and business strategy, in connection with acquisitions, to adjust our ratio of debt to equity, to satisfy our obligations upon the exercise of outstanding warrants or options or for other reasons.
There may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock.
In the future, we may need to raise additional funds through public or private financing, which might include sales of equity securities. The issuance of any additional shares of common stock or securities convertible into, exchangeable for, or that represent the right to receive common stock or the exercise of such securities could be substantially dilutive to holders of shares of our common stock. Holders of shares of our common stock have no preemptive rights that entitle holders to purchase their pro rata share of any offering of shares of any class or series. The market price of our common stock could decline as a result of sales of shares of our common stock made after this offering or the perception that such sales could occur. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, our stockholders bear the risk of our future offerings reducing the market price of our common stock and diluting their interests in our Company.
Provisions in our certificate of incorporation and Delaware law could discourage a change in control, or an acquisition of us by a third party, even if the acquisition would be favorable to you.
Our certificate of incorporation and the Delaware General Corporation Law contain provisions that may have the effect of making more difficult or delaying attempts by others to obtain control of our Company, even when these attempts may be in the best interests of stockholders. For example, our certificate of incorporation authorizes our Board of Directors, without stockholder approval, to issue one or more series of preferred stock, which could have voting and conversion rights that adversely affect or dilute the voting power of the holders of common stock. Delaware law also imposes conditions on certain business combination transactions with “interested stockholders.” These provisions and others that could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in our control or management, including transactions in which stockholders might otherwise receive a premium for their shares over then current market prices. These provisions may also limit the ability of stockholders to approve transactions that they may deem to be in their best interests.
We do not expect to pay dividends in the foreseeable future.
We have paid no cash dividends on our common stock to date, and we intend to retain our future earnings, if any, to fund the continued development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Further, any payment of cash dividends will also depend on our financial condition, results of operations, capital requirements and other factors, including contractual restrictions to which we may be subject, and will be at the discretion of our Board of Directors.
A few of our outstanding warrants contain anti-dilution provisions that, if triggered, could cause dilution to our then-existing stockholders and adversely affect our stock price.
A few of our outstanding warrants contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock or other securities convertible into our common stock for a per share price less than the exercise price of our warrants, the exercise price, or in the case of some of our warrants the exercise price and number of shares of common stock, will be reduced. If our available funds and cash generated from operations are insufficient to satisfy our liquidity requirements in the future, then we may need to raise substantial additional funds in the future to support our working capital requirements and for other purposes. If shares of our common stock or securities exercisable for our common stock are issued in consideration of such funds at an effective per share price lower than our existing warrants, then the anti-dilution provisions would be triggered, thus possibly causing dilution to our then-existing shareholders if such warrants are exercised. Such anti-dilution provisions may also make it more difficult for us to obtain financing.
The exercise of our outstanding warrants may result in a dilution of our current stockholders' voting power and an increase in the number of shares eligible for future resale in the public market, which may negatively impact the market price of our stock.
The exercise of some or all of our outstanding warrants could significantly dilute the ownership interests of our existing stockholders. As of March 19, 2019, we had outstanding warrants to purchase an aggregate of 1,584,829 shares of common stock at exercise prices ranging from $1.80 to $12.00 per share. To the extent warrants are exercised, additional shares of common stock will be issued, and such issuance may dilute existing stockholders and increase the number of shares eligible for resale in the public market.
In addition to the dilutive effects described above, the exercise of those warrants would lead to a potential increase in the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect the market price of our shares.
ITEM 1B. UNRESOLVED STAFF COMMENTS
Not Applicable.
ITEM 2. PROPERTIES
Information concerning our principal facilities, all of which were leased at December 31, 2018, is set forth below:
|
|
| |||
|
| ||||
Our principal executive and administrative offices are located in Los Angeles, California, and consists of leased office space totaling approximately 9,120 square feet, which will expire in April 2019. Our base rent is currently approximately $33,000 per month. In September 2018, we entered into a lease for our new corporate offices located in Santa Monica, CA for 7,869 rentable square feet. The lease is for 48 months beginning in April 2019 with a base rent of approximately $48,000, subject to annual adjustments.
We believe that the current office space is adequate to meet our needs.
ITEM 3. LEGAL PROCEEDINGS
From time to time, we are subject to various legal proceedings that arise in the normal course of our business activities. As of the date of this Annual Report on Form 10-K, we are not a party to any litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations or financial position.
ITEM 4. MINE SAFETY AND DISCLOSURE
Not Applicable.
PART |
|
|
Market Information
Our common stock is listed on the NASDAQ Capital Market under the symbol “CATS.”
Stockholders
As of March 19, 2019, there were approximately 31 stockholders of record of our 16,205,146 outstanding shares of common stock. This number does not include beneficial owners whose shares are held in “street name.”
Dividends
We have never declared or paid dividends on our common stock and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on applicable law and then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business.
Information about our Equity Compensation Plans
Information regarding our equity compensation plans is incorporated by reference to Item 10, “Directors, Executive Officers and Corporate Governance” of Part III of this Annual Report on Form 10-K.
Unregistered Sales of Securities
All sales of unregistered securities during the year ended December 31, 2018 were previously disclosed in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.
Issuer Purchase of Equity Securities
None.
|
|
Not applicable.
|
|
Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed due to factors such as, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry. Additional information concerning factors that could cause or contribute to such differences can be found in the following discussion, as well as in Item 1.A.-“Risk Factors.”
OVERVIEW
General
We harness proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and cost savings to health plans. We identify, engage and treat health plan members with unaddressed behavioral health conditions that worsen medical comorbidities. Our mission is to help improve the health and save the lives of as many people as possible.
We apply advanced data analytics and predictive modeling to identify members with untreated behavioral health conditions, whether diagnosed or not, and coexisting medical conditions that may be impacted through treatment in the OnTrak program. We then uniquely engages health plan members who do not typically seek behavioral healthcare by leveraging proprietary enrollment capabilities built on deep insights into the drivers of care avoidance. Our technology enabled OnTrak solution is an integrated suite of services that includes evidence-based psychosocial and medical interventions delivered either in-person or via telehealth, nurse-led care coaching and local community support. We believe that the program is currently improving member health and, at the same time, demonstrating reduced medical utilization, driving a reduction in total health plan costs for enrolled members.
We have contracted with leading national and regional health plans to make OnTrak available to eligible members in California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, Nebraska, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.
Our Strategy
Our business strategy is to deliver proven, repeatable clinical and financial outcomes to health plans for their members with unaddressed behavioral conditions that worsen medical comorbidities. We do this by identifying, engaging and treating these members through our OnTrak solution. Our initial focus was members with substance use disorder(s), and today our solution also addresses anxiety disorders and depression.
Key elements of our business strategy include:
|
|
|
|
|
|
|
|
Key elements of our growth strategy include:
|
|
|
|
|
|
|
|
ReportingSegment
We manage and report our operations through one business segment: healthcare services. The healthcare services segment includes the OnTrak solutions marketed to health plans and other third party payors.
Summary financial information for our reportable segment is as follows:
Results of Operations
The table below and the discussion that follows summarize our results of operations and certain selected operating statistics for the last two fiscal years ended December 31, 2018 and 2017:
Year Ended | ||||||||
(In thousands, except per share amounts) | December 31, | |||||||
2018 | 2017 | |||||||
Revenues | ||||||||
Healthcare services revenues | $ | 15,177 | $ | 7,717 | ||||
Operating expenses | ||||||||
Cost of healthcare services | 11,119 | 6,391 | ||||||
General and administrative | 17,395 | 11,811 | ||||||
Depreciation and amortization | 288 | 246 | ||||||
Total operating expenses | 28,802 | 18,448 | ||||||
Loss from operations | (13,625 | ) | (10,731 | ) | ||||
Other income | 40 | 132 | ||||||
Interest expense | (570 | ) | (3,409 | ) | ||||
Loss on conversion of note | - | (1,356 | ) | |||||
Loss on issuance of common stock | - | (145 | ) | |||||
Change in fair value of warrant liability | (56 | ) | 1,778 | |||||
Change in fair value of derivative liability | - | 132 | ||||||
Loss before provision for income taxes | (14,211 | ) | (13,599 | ) | ||||
Provision for income taxes | 1 | 6 | ||||||
Net loss | $ | (14,212 | ) | $ | (13,605 | ) | ||
Year ended December 31, 2018 compared with year ended December 31, 2017
Summary of Consolidated Operating Results
Loss from operations before provision for income taxes for the year ended December 31, 2018 was $14.2 million compared with $13.6 million for the year ended December 31, 2017. Our $7.5 million increase in revenues were offset by the investment in cost of healthcare services due to the increase in headcount needed to service our increase in enrolled members, investments in technology and product to drive efficiencies, and included a non-cash share-based compensation expense of $2.1 million related to options issued in December 2017 and throughout 2018.
Revenues
During the year ended December 31, 2018, we launched enrollment with three new health plans in the states of Illinois, Tennessee and California, expanded with several of our current health plans into new service lines, and expanded with another of our health plans into four new states. We have continued to increase enrollment, which has resulted in a net increase in the number of patients enrolled in our OnTrak solutions compared with the same period in 2017, this was offset by the timing of billing for certain members who we bill on a per claim basis. For the year ended December 31, 2018 newly enrolled members increased by 120% over the same period in 2017. Recognized revenue increased by $7.5 million, or 97%, for the year ended December 31, 2018, compared with the same period in 2017, respectively.
Operating Expenses
Cost of Healthcare Services
Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists, healthcare provider claims payments to our network of physicians and psychologists, and fees charged by our third party administrators for processing these claims. The increase of $4.7 million, or 74%, for the year ended December 31, 2018, compared with the same period in 2017, respectively, relates primarily to the increase in members being treated, the addition of care coaches, outreach specialists, community care coordinators and other staff to manage the increasing number of enrolled members. In addition, we hire staff in preparation for anticipated future customer contracts and corresponding increases in members eligible for OnTrak.
General and Administrative Expenses
Total general and administrative expense increased by $5.6 million, or 47%, for the year ended December 31, 2018, compared with the same period in 2017. The increase in general and administrative expenses was primarily related to investments in data science, IT and software development to support growth and drive efficiency. In addition, there was an increase of approximately $2.1 million in non-cash share-based compensation expense during the twelve months of 2018 related to the issuance of stock options in December 2017 and throughout 2018.
We expect our general and administrative expenses to increase for the foreseeable future as we continue to grow our business. However, we expect our general and administrative expenses to decrease significantly as a percentage of our total revenue over the next several years. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.
Interest Expense
Interest expense decreased by approximately $2.8 million year ended December 31, 2018 compared with the same periods in 2017. The decrease during the year ended December 31, 2018 primarily relates to the convertible debentures and warrants issued in connection with our convertible debentures during 2017. The majority of these instruments were either converted to equity or paid in full in April 2017 and as a result interest expense significantly decreased for the year ended December 31, 2018. This was partially offset by the interest expense incurred in 2018 related to the issuance of the venture loan and security agreement with Horizon Technology Finance Corporation and amortization of debt discount associated with the loan.
Loss of conversion of note
Loss on conversion of note during the year ended December 31, 2017 relates to the conversion of the July 2015 convertible debenture and a portion of the December 2016 convertible debentures during 2017. No such conversion occurred during 2018.
Change in Fair Value of Warrant Liability
We have 11,049 warrants to purchase common stock which are being accounted for as liabilities in accordance with accounting standards, due to anti-dilution provisions in the warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.
The decrease in the loss from change in fair value for the warrants was $1.8 million for the year ended December 31, 2018 compared with the same period in 2017. The decrease primarily relates to the removal of anti-dilution protection in most of our outstanding warrants in April 2017 and thus that portion of the liability was transferred to equity.
Liquidity and Capital Resources
Liquidity and Capital Resources
Cash, cash equivalents and restricted cash was $3.6 million as of December 31, 2018. As of March 19, 2019, we had a balance of approximately $2.5 million cash on hand. We had working capital deficit of approximately $2.2 million as of December 31, 2018. We have incurred significant net losses and negative operating cash flows since our inception. We expect to continue to incur negative cash flows and net losses for the next twelve months. Our average cash burn rate is approximately $762,000 per month. We expect our current cash resources to cover expenses through at least the next twelve months, however, delays in cash collections, revenue, or unforeseen expenditures could impact this estimate.
In June 2018, we entered into a venture loan and security agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Horizon”), which provides for up to $7.5 million in loans to the Company, including initial loans in the amount of $5.0 million funded upon signing of the Loan Agreement. An additional $2.5 million loan was subject to the Company’s achievement of billings of not less than $5.0 million during any three consecutive month period on or prior to November 30, 2018. In August 2018, we incurred the additional $2.5 million loan as a result of our achievement of the trailing three month billings exceeding $5.0 million on or prior to November 30, 2018. Also, in June 2018, we entered into a loan and security agreement in connection with a $2.5 million receivables financing facility with Corporate Finance, a division of Heritage Bank of Commerce (the “A/R Facility”). The A/R Facility provides for the borrower entities to borrow up to 85% of the Company’s eligible accounts receivable, as defined in the A/R Facility. In February 2019, we borrowed $976,000 on the A/R Facility twice during the month, of which none is outstanding as of March 19, 2019.
In March 2019, we entered into an amended and restated venture loan and security agreement (as so amended and restated, the “Amended Loan Agreement”) with Horizon, including initial term loans in the amount of $7.5 million previously funded under the original Loan Agreement entered into in June 2018 and an additional up to $7.5 million loan in three revolving tranches of $2.5 million in availability, subject to the Company’s achievement of trailing three month billings exceeding $5.0 million, $7.0 million and $8.0 million, respectively. An initial advance of $2.5 million was funded upon the execution and delivery of the Loan Agreement, subject to repayment if the foregoing $5.0 million threshold is not reached by July 1, 2019. We concurrently entered into an amendment to the previously disclosed $2.5 million A/R Facility with Corporate Finance intended primarily to reflect the amendment and restatement of the Amended Loan Agreement.
Our ability to fund our ongoing operations is dependent on increasing the number of members that are eligible for our solutions by signing new contracts, identifying more eligible members in existing contracts, and generating fees from existing and new contracts and the success of management’s plan to increase revenue and continue to control expenses. We currently operate our OnTrak solutions in twenty-two states. We provide services to commercial (employer funded), managed Medicare Advantage, and managed Medicaid and duel eligible (Medicare and Medicaid) populations. We have generated fees from our launched programs and expect to increase enrollment and fees throughout 2019.
Historically, we have seen and continue to see net losses, net loss from operations, negative cash flow from operating activities, and historical working capital deficits as we continue through a period of rapid growth. The accompanying financial statements do not reflect any adjustments that might result if we were unable to continue as a going concern. We have alleviated substantial doubt by both entering into contracts for additional revenue-generating health plan customers and expanding our OnTrak program within existing health plan customers. To support this increased demand for services, we invested and will continue to invest in additional headcount needed to support the anticipated growth. Additional management plans include increasing the outreach pool as well as improving our current enrollment rate. We will continue to explore ways to increase margins on both existing and new members.
We have a growing customer base and believe we are able to fully scale our operations to service the contracts and future enrollment providing leverage in these investments that will generate positive cash flow by the end of 2019. We believe we will have enough capital to cover expenses through the foreseeable future and we will continue to monitor liquidity. If we add more health plans than budgeted, increase the size of the outreach pool by more than we anticipate, decide to invest in new products or seek out additional growth opportunities, we would consider financing these options with either a debt or equity financing.
Cash Flows
We used $8.6 million of cash from operating activities during the year ended December 31, 2018 compared with $7.4 million during the same period in 2017. The increase primarily relates to the increase in members being treated, the addition of care coaches, outreach specialists, community care coordinators and other staff to manage the increasing number of enrolled members, and investments in data science, IT and software development to support growth and drive efficiency.
Capital expenditures for the year ended December 31, 2018 were not material. We anticipate that capital expenditures will increase in the future as we replace our computer systems that are reaching the end of their useful lives, upgrade equipment to support our increased number of enrolled members, and enhance the reliability and security of our systems. These future capital expenditure requirements will depend upon many factors, including obsolescence or failure of our systems, progress with expanding the adoption of our solutions, our marketing efforts, the necessity of, and time and costs involved in obtaining, regulatory approvals, competing technological and market developments, and our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements.
Our net cash provided by financing activities was $7.3 million for the year ended December 31, 2018, compared with net cash provided by financing activities of $11.7 million for the year ended December 31, 2017. Cash provided by financing activities for the year ended December 31, 2018 consisted of the gross proceeds from the issuance of debt in the amount of $7.5 million, proceeds from warrant exercise of $150,000, offset by debt issuance costs of $317,000, and capital lease obligations of $30,000.
As a result of the above our cash, cash equivalents and restricted cash balance as of December 31, 2018 is $3.6 million.
As discussed above, we currently expend cash at a rate of approximately $762,000 per month. We also anticipate cash inflow to increase during 2019 as we continue to service our executed contracts and sign new contracts. We expect our current cash resources to cover our operations through at least the next twelve months, however, delays in cash collections, revenue, or unforeseen expenditures could impact this estimate.
Off-Balance Sheet Arrangements
As of December 31, 2018, we had no off-balance sheet arrangements.
Critical Accounting Estimates
The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. We base our estimates on experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that may not be readily apparent from other sources. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. Our actual results may differ from these estimates.
We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different results when using different assumptions. We have discussed these critical accounting estimates, the basis for their underlying assumptions and estimates, and the nature of our related disclosures herein with the audit committee of our Board of Directors. We believe our accounting policies related to revenue recognition and share-based compensation expense involve our most significant judgments and estimates that are material to our consolidated financial statements. They are discussed further below.
Revenue Recognition
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606),(“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The FASB has issued numerous updates that provide clarification on a number of specific issues as well as requiring additional disclosures. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.
We adopted ASC 606 effective January 1, 2018 using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09were as follows (in thousands):
Balance at December 31, 2017 | Adjustments Due to Adoption of ASC606 | Balance at January 1, 2018 | ||||||||||
| Balance Sheet | ||||||||||||
Liabilities | ||||||||||||
Deferred revenue | (2,914 | ) | 1,881 | (1,033 | ) | |||||||
Equity | ||||||||||||
Retained earnings | (293,324 | ) | 1,881 | (291,443 | ) | |||||||
In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated income statement and balance sheet for the year ended December 31, 2018 was as follows (in thousands):
Year Ended December 31, 2018 | ||||||||||||
As | Balances Without Adoption of | Effect of Change | ||||||||||
Income Statement | ||||||||||||
Revenues | ||||||||||||
Healthcare services revenues | $ | 15,177 | $ | 9,349 | $ | 5,828 | ||||||
Net loss | (14,212 | ) | (20,040 | ) | 5,828 | |||||||
Share-based compensation expense
We account for the issuance of stock, stock options and warrants for services from non-employees based on an estimate of the fair value of options and warrants issued using the Black-Scholes pricing model. This model’s calculations include the exercise price, the market price of shares on grant date, weighted average assumptions for risk-free interest rates, expected life of the option or warrant, expected volatility of our stock and expected dividend yield.
The amounts recorded in the financial statements for share-based compensation expense could vary significantly if we were to use different assumptions. For example, the assumptions we have made for the expected volatility of our stock price have been based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. If we were to use a different volatility than the actual volatility of our stock price, there may be a significant variance in the amounts of share-based expense from the amounts reported. The weighted average expected option term for the year ended December 31, 2018 and 2017 reflects the application of the simplified method set out in SEC Staff Accounting Bulletin No. 107, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.
From time to time, we retain terminated employees as part-time consultants upon their resignation from the Company. Because the employees continue to provide services to us, their options continue to vest in accordance with the terms set forth under their original grants. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards and are accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. There were no employees moved to consulting status for the year ended December 31, 2018 and 2017, respectively.
Recently Issued or Newly Adopted Accounting Pronouncements
In August 2018, the FASB issued Accounting Standard Update (“ASU”) No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. For public companies, the amendments are effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted. We are currently assessing the impact that adopting this new accounting guidance will have on its financial statements and footnote disclosures.
In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. For public companies, the amendments are effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but no earlier than a company's adoption date of ASC 606. We do not believe that the adoption of ASU 2018-07 will have a material impact on our consolidated financial statements.
In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). The amendments in this update are intended to simplify the accounting for certain equity linkedfinancial instruments and embedded features with down round features that result in the strike price being reduced on the basis of the pricing of futureequity offerings. Under the new guidance, a down round feature will no longer need to be considered when determining whether certain financial instrumentsor embedded features should be classified as liabilities or equity instruments. That is, a down round feature will no longer preclude equity classification whenassessing whether an instrument or embedded feature is indexed to an entity's own stock. In addition, the amendments clarify existing disclosurerequirements for equity-classified instruments. These amendments are effective for fiscal years, and interim periods within those years, beginning afterDecember 15, 2018, with early adoption permitted. We do not believe that the adoption of ASU 2017-11 will have a material impact on our consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU 2016-18, restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU 2016-18 as of January 1, 2018. The following is a summary of cash, cash equivalents and restricted cash total as presented in the statements of cash flows for the years December 31, 2018, and 2017:
(in thousands) | 2018 | 2017 | ||||||
Cash and cash equivalents | $ | 3,091 | $ | 4,779 | ||||
Restricted cash (current and long-term) | 479 | - | ||||||
Total cash, cash equivalents and restricted cash | $ | 3,570 | $ | 4,779 | ||||
In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606) (“ASU 2016-10”), which amends certain aspects of the Board’s new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09, which is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. We have selected the modified retrospective approach as our transition method under ASU 2016-10 and the financial impact to the financial statements was to decrease retained earnings and deferred revenue by $1.9 million effective January 1, 2018 (Please see footnote 5).
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (“ASU 2016-13”). The amendment revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to, available for sale debt securities and accounts receivable. The Company is required to adopt this standard starting in the first quarter of fiscal year 2021. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements and related disclosures.
In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). Under this standard, which applies to both lessors and lessees, lessees will be required to recognize all leases (except for short-term leases) as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease measured on a discounted basis, and as a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018 and is to be applied at the beginning of the earliest period presented using a modified retrospective approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available. Based on the Company’s leases in place on January 1, 2019 and considering the practical expedients, the Company expects that adoption of the new standard will not have a material effect on its consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than $200,000 and will have no effect on our consolidated statements of cash flows.
Effects of Inflation
Our most liquid assets are cash and cash equivalents. Because of their liquidity, these assets are not directly affected by inflation. Because we intend to retain and continue to use our equipment, furniture, and fixtures and leasehold improvements, we believe that the incremental inflation related to replacement costs of such items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation and contract services, which could increase our level of expenses and the rate at which we use our resources.
|
|
Not applicable.
|
|
Our consolidated financial statements and related financial information required to be filed hereunder are indexed under Item 15 of this report and are incorporated herein by reference.
|
|
Not applicable.
|
|
Evaluation of Disclosure Controls and Procedures
We have evaluated, with the participation of our principal executive officer and our principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control
There were no changes in our internal controls over financial reporting during the fourth quarter of our year ended December 31, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Management's Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) and for assessing the effectiveness of our internal control over financial reporting. Our internal control system is designed to provide reasonable assurance to our management and Board of Directors regarding the preparation and fair presentation of published financial statements in accordance with United States generally accepted accounting principles (GAAP).
Our internal control over financial reporting is supported by written policies and procedures that:
|
| |
|
| |
|
|
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2018, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013). Management's assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of our internal control over financial reporting. Based upon this assessment, our management believes that, as of December 31, 2018, our internal control over financial reporting was effective based on those criteria.
Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance and may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions and that the degree of compliance with the policies or procedures may deteriorate.
ITEM 9B.OTHER INFORMATION
None.
|
| 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
The following table lists our executive officers and directors serving at March 19, 2019.April 24, 2020. Our executive officers are elected annually by our Board of Directors and serve at the discretion of the Board of Directors. Each current director is serving a term that will expire at the Company's next annual meeting. There are no family relationships among any of our directors or executive officers.
Name | Age | Position | Officer/ Director Since |
| Age |
| Position |
| Director Since | |||
Terren S. Peizer | 59 | Director, Chairman of the Board and Chief Executive Officer | 2003 |
| 59 |
| Director, Chairman of the Board and Chief Executive Officer |
| 2003 | |||
Richard A. Anderson | 49 | President and Chief Operating Officer | 2003 | |||||||||
Christopher Shirley | 43 | Chief Financial Officer | 2017 | |||||||||
Brandon H. LaVerne (1) |
| 48 |
| Chief Financial Officer | - | |||||||
Curtis Medeiros (2) | 45 | President and Chief Operating Officer | - | |||||||||
Richard A. Berman | 74 | Director, Chairman of the Audit Committee, and Member of the Nomination and Corporate Governance Committee | 2014 |
| 74 |
| Director, Chairman of the Audit Committee, and Member of the Nomination and Governance Committee |
| 2014 | |||
Richard J. Berman | 76 | Director, Member of the Audit Committee and Member of the Compensation Committee | 2017 | |||||||||
Michael Sherman | 59 | Director, Chairman of the Compensation Committee and Chairman of the Nomination and Corporate Governance Committee | 2017 |
| 59 |
| Director, Chairman of the Compensation Committee and Chairman of the Nomination and Governance Committee |
| 2017 | |||
Edward J. Zecchini | 58 | Director, Compensation Committee Member | 2018 | |||||||||
Sharon R. Gabrielson | 57 | Director, Nomination and Corporate Governance Committee Member | 2018 | |||||||||
Edward Zecchini |
| 58 |
| Director, Compensation Committee Member |
| 2018 | ||||||
Diane Seloff | 55 | Director and Audit Committee Member | 2018 |
| 55 |
| Director and Audit Committee Member |
| 2018 | |||
Robert Rebak (3) |
| 52 |
| Director, Nomination and Governance Committee Member |
| 2019 | ||||||
Gustavo Giraldo (4) |
| 48 |
| Director, Member of the Audit Committee and Member of the Compensation Committee |
| 2019 | ||||||
(1) Mr. LaVerne was appointed to serve as the Chief Financial Officer of the Company on March 16, 2020.
(2) Mr. Curtis Medeiros was appointed to serve as the President and Chief Operating Officer of the Company replacing Mr. Richard Anderson on December 2, 2019.
(3) Mr. Rebak was appointed to serve as a member of the board of directors in July 2019.
(4) Mr. Giraldo was appointed to serve as a member of the board of directors in November 2019.
Terren S. Peizer is the founder of our Company and an entrepreneur, investor, and financier with a particular interest in healthcare, having founded and successfully commercialized several healthcare companies. He has served as its Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in 2004. Mr. Peizer is also the founder, Chairman and CEO NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. In addition to his roles with Catasys and NeurMedix, Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal investment vehicle, and holding company that is the owner of all of his portfolio company interests. Through Acuitas, Mr. Peizer owns Acuitas Capital, LLC, an industry leader in investing in micro and small capitalization equities, having invested over $1.5 billion directly into portfolio companies. Mr. Peizer has been the largest beneficial shareholder of, and has held various senior executive positions with, several other publicly-traded growth companies, including having served as Chairman of Cray, Inc. a supercomputer company. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce.
We believe Mr. Peizers’sPeizer’s qualifications to serve on our board of directors include his role as an investor and executive positions in several private and public companies, including numerous companies in the healthcare field. He has extensive knowledge and experience in the financial and healthcare industries and provides extensive insight and experience with capital markets and publicly traded companies at all stages of development.
Richard A. AndersonBrandon H. LaVerne has served as the Company’s Chief Financial Officer since March 2020. Prior to joining the Company, Mr. LaVerne worked at PCM, Inc. from October 1998 until its sale in August 2019 and most recently served as its Chief Financial Officer, Chief Accounting Officer, Treasurer and Assistant Secretary since July 2007. Prior to joining PCM, Inc. Mr. LaVerne worked as the Corporate Accounting Supervisor for Computer Sciences Corporation from September 1996 to October 1998, and started his career with Deloitte & Touche LLP in September 1993. Mr. LaVerne received his Bachelor of Science in Accounting from University of Southern California and is a Certified Public Accountant.
Curtis Medeiros has served as a member of our management team since April 2005 and previously served as a director from July 2003 to November 2018. He has been our President and Chief Operating Officer since July 2008; in this role he has been primarily responsible for the creation and leadership of our OnTrak solution. He has more than twenty-five years of experience in business development, strategic planning, operations, finance and management, with more than 15 years of that in the healthcare field.December 2019. Prior to joining the Company, Mr. Medeiros was the President at OPTUM Analytics overseeing a group that served the analytical needs of external payers, providers and life sciences companies since July 2019. Mr. Medeiros was the President of OPTUM Life Sciences at UnitedHealth Group from 2014 to April 2016, where he focused on creating novel collaboration opportunities that addressed health system challenges. From June 2014 to April 2016, Mr. Medeiros was the Chief Operating Officer and Senior Vice President at OPTUM Life Sciences where he led the OPTUM Life Sciences business, which drives client value by providing best in class real-world data, analytics, consulting and collaborations aimed at improving the health care system for all stakeholders. Prior to joining OPTUM in June 2010, Mr. Medeiros served as a Senior Director at Merck Research Laboratories from January 2009 to May 2010. Mr. Medeiros holds a bachelor’s degree in Chemical Engineering from MIT and an MBA from Harvard Business School.
Richard A. Berman has served as the Company’s director since 2014. Heis the Associate Vice President of Strategic initiatives for the University of South Florida Research and Innovation, visiting professor of social entrepreneurship in the Muma College of Business, and a professor in the institute of innovation and advanced discovery. As a recognized global leader, Mr. Berman has held positions in health care, education, politics and management. He has worked with several foreign governments, the United Nations, the U.S. Department of Health and Welfare, the FDA, and as a cabinet level official for the state of New York. He has also worked with McKinsey & Co, NYU Medical Center, Westchester Medical, Korn-Ferry International, Howe-Lewis International and numerous startup companies. In 1995, Mr. Berman was selected by Manhattanville College to serve as its tenth President. Mr. Berman is credited with the turnaround of the College, where he served until 2009. Mr. Berman serves on the board of several organizations and is an elected member of the National Academy of Medicine of the National Academy of Sciences (Formerly known as the Institute of Medicine). Mr. Berman received his BBA, MBA, and MPH from the University of Michigan and holds honorary doctorates from Manhattanville College and New York Medical College.
We believe Mr. Berman’s qualifications to serve on our board of directors include his extensive experience as an executive in several healthcare firms. In addition, as a board member of a health plan we believe he has an understanding of our customer base and current developments and strategies in the health insurance industry.
Michael Sherman has served as the Company’s director since July 2017. He has worked in finance for over 30 years, having last served as a Managing Director in Investment Banking, at Barclays Plc. Prior to Barclays, Mr. Sherman was at Lehman Brothers, Inc. and Salomon Brothers Inc. Mr. Sherman specialized in equity capital markets and covered Healthcare companies, in addition to companies in other sectors. Mr. Sherman also is currently a Board Member at BioVie, Inc., a specialty pharmaceutical company. Mr. Sherman began his career in finance as a lawyer at Cleary, Gottlieb, Steen & Hamilton in New York City and Hong Kong.
We believe that Mr. Sherman’s qualifications to serve on our board of directors include his experience in the banking and securities industry, and his experience in the healthcare industry.
Edward Zecchini has served as the Company’s director since October 2018. Mr. Zecchini currently serves as Managing Member of IT Analytics LLC. Prior to that, Mr. Zecchini served as Chief Information Officer at Remedy Partners, Inc. from April 2014 to October 2019, Executive Vice President and Chief Technology Officer at Sandata Technologies, LLC, from May 2010 to March 2014. Earlier in his career he held senior level financialpositions at HealthMarkets, Inc., Thomson Healthcare and operational positionsSportsTicker, Inc. Mr. Zecchini has over thirty years of experience in the healthcare and information technology industries. Mr. Zecchini holds a Bachelor of Arts degree from the State University of New York at Oswego. Mr. Zecchini’s business expertise, including his background and extensive experience in information technology and management makes him well-qualified to serve as a member of the board of directors. He is also a Director of Cryoport Inc. Mr. Zecchini became a member of the Cryoport, Inc. (NASDAQ: symbol “CYRX.”) board of directors in September 2013 and serves as Chairman of the Compensation Committee and member of the Audit Committee and Scientific and Technology Committee
We believe Mr. Zecchini’s qualifications to serve on our board of directors include his experience in the healthcare industry, and his current and past experience in numerous private and publicly traded companies.
Diane Seloff has served as the Company’s director since October 2018. She is currently the Interim Chief Operating Officer at CareBridge and was part of the founding leadership team. She served as Chief Operating Officer at Aspire Health since October 2013 through August 2019 including engaged in the sale to Anthem in June of 2018 and led the integration with Anthem and CareMore. As Aspire Health’s Chief Operating Officer, Ms. Seloff built all the corporate functions for the company in its first two years and was responsible for running and transforming Aspire Health’s operations. She previously held senior executive roles in operations and development at other healthcare services and technology companies, including Vanderbilt University Medical Center from October 2007 to July 2013. Ms. Seloff began her career as a management consultant—first at Arthur Andersen & Company and later at KPMG Peat Marwick. Ms. Diane Seloff possesses over 25 years of experience in the broader healthcare industry and has diverse experience in operations, human capital, finance, technology, strategic planning and business development in healthcare, financial services, and financial companies,logistics. Ms. Seloff received her MBA from Columbia University in 1990 and served as a directorreceived her BS in PriceWaterhouseCoopers LLP’s business assurance and transaction support practices. He received a B.A. in Business EconomicsEngineering from University of California, Santa Barbara.Michigan in 1984.
We believe Ms. Seloff’s qualifications to serve on our board of directors include her extensive experience as an executive in several healthcare firms. In addition, as a board member we believe she has an understanding of our customer base and current developments and strategies in the health insurance industry.
Robert Rebak has served as the Company’s director since July 2019. Mr. Rebak currently serves as the Chief Executive Officer of Forefront Telecare, a behavioral telehealth company serving seniors in rural health systems in 20 US states, where he is responsible for company vision, strategy, growth, culture, and overall operating performance since January 2019. From June 2016 to June 2018, he served as the President and Chief Executive Officer of AbleTo, a behavioral telehealth company serving adult health plan members nationwide. From November 2014 to March 2016, he served as President, Consumer Solutions for Sharecare, a health and wellness patient engagement platform. He joined Sharecare through its acquisition of QualityHealth, a digital patient acquisition and engagement platform, where he was Chairman and Chief Executive Officer from February 2009 to November 2014. Mr. Rebak previously served as Managing Partner of Rosetta, from June 2005 to January 2007. He joined Rosetta through its acquisition of SimStar, where he served as President of the healthcare-specific digital marketing firm from February 1999 to June 2005. He has raised over $60 million in growth capital from both strategic and financial investors and has led two successful company sale transactions. Mr. Rebak has served on both private equity backed companies and not-for-profit Boards, and currently serves as a Board Director of the Quell Foundation. Mr. Rebak holds an MBA in Finance and Marketing from the University of Chicago Booth School of Business and a BA in History and Economics from Vanderbilt University.
We believe Mr. Rebak ’s qualifications to serve on our board of directors include his experience in the banking and securities industry and his experience in the healthcare industry.
Gustavo Giraldo has served as the Company’s director since November 2019. Mr. Giraldo currently serves as the Regional Vice President and the Head of Latin America for Centene Corporation. From April 2016 to December 2019, Mr. Giraldo served as the president of behavioral and specialty health at Magellan Healthcare, where he has been responsible for the strategic development and profitable growth of Magellan Healthcare’s health plan, employer, provider segments, state carve-out behavioral health and federal markets. From April 2015 to April 2016, Mr. Giraldo served as the Chief Operating Officer for Chubb’s Latin American life, accident and health business where he was responsible for the lead sales and distribution for a division of the company. He served as the Chief Operating Officer of Cigna’s Chinese life insurance joint venture from September 2001 to March 2015, and the Founder and Regional Managing Director for Cigna’s Asian health insurance businesses. Mr. Giraldo has more than 20 years of leadership in the insurance industry, including a track record of initiating, leading and growing domestic and global healthcare businesses. Mr. Giraldo earned his bachelor’s degree in mathematics from The Florida State University in 1996 and his master’s degree in business administration from the University of Pennsylvania’s Wharton School of Business in 2006.
We believe Mr. Giraldo’s qualifications to serve on our board of directors include his experience in the healthcare industry and his current and past experience in numerous private and publicly traded companies.
Independence of the Board of Directors
Our common stock is traded on the NASDAQ Capital Market. The Board of Directors has determined that six of the members of the Board of Directors qualify as “independent,” as defined by the listing standards of the NASDAQ. Consistent with these considerations, after review of all relevant transactions and relationships between each director, or any of his family members, and the Company, its senior management and its independent auditors, the Board has determined further that Messrs. Berman, Sherman, Zecchini, Rebak, Giraldo and Ms. Seloff are independent under the listing standards of NASDAQ. In making this determination, the Board of Directors considered that there were no new transactions or relationships between its current independent directors and the Company, its senior management and its independent auditors since last making this determination.
2019 Meetings and Attendance
During 2019, the Board held 5 meetings. All Directors attended at least 75% or more of the aggregate number of meetings of the Board and Board Committees on which they served.
Committees of the Board of Directors
Audit committee
Our audit committee currently consists of three directors, Messrs. Berman and Giraldo and Ms. Seloff with Mr. Berman serving as the chairman of the audit committee. Mr. Giraldo was appointed to serve as a member of the Audit Committee in November 2019. The audit committee had 4 meetings during the 2019 year. The Board of Directors has determined that each of the members of the audit committee were independent as defined by the NASDAQ rules, meet the applicable requirements for audit committee members, including Rule 10A-3(b) under the Exchange Act, and that Mr. Berman qualifies as an “audit committee financial expert” as defined by Item 401(h)(2) of Regulation S-K. The duties and responsibilities of the audit committee include (i) selecting, evaluating and, if appropriate, replacing our independent registered accounting firm, (ii) reviewing the plan and scope of audits, (iii) reviewing our significant accounting policies, any significant deficiencies in the design or operation of internal controls or material weakness therein and any significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation and (iv) overseeing related auditing matters.
A copy of the audit committee’s written charter is publicly available through the “Investors-Governance” section of our website at www.catasys.com.
Nominations and governance committee
Our nominations and governance committee currently consists of three members Messrs. Sherman, Berman and Rebak, who are all independent as defined by the NASDAQ rules. Mr. Rebak was appointed to serve as a member of the nominations and governance committee in November 2019. The nominations and governance committee had 5 meetings during 2019. Mr. Sherman serves as the chairman of the nominations and governance committee. The committee nominates new directors and periodically oversees corporate governance matters.
The charter of the nominations and governance committee provides that the committee will consider board candidates recommended for consideration by our stockholders, provided the stockholders provide information regarding candidates as required by the charter or reasonably requested by us within the timeframe proscribed in Rule 14a-8 of Regulation 14A under the Exchange Act, and other applicable rules and regulations. Recommendation materials are required to be sent to the nominations and governance committee c/o Catasys, Inc., 2120 Colorado Ave., Suite 230, Santa Monica, CA 90404. There are no specific minimum qualifications required to be met by a director nominee recommended for a position on the board of directors, nor are there any specific qualities or skills that are necessary for one or more of our directors to possess, other than as are necessary to meet any requirements under the rules and regulations applicable to us. The nominations and governance committee considers a potential candidate's experience, areas of expertise, and other factors relative to the overall composition of the board of directors.
The nominations and governance committee considers director candidates that are suggested by members of the board of directors, as well as management and stockholders. The committee may also retain a third-party executive search firm to identify candidates. The process for identifying and evaluating nominees for director, including nominees recommended by stockholders, involves reviewing potentially eligible candidates, conducting background and reference checks, interviews with the candidate and others (as schedules permit), a meeting to consider and approve the candidate and, as appropriate, preparing and presenting to the full board of directors an analysis with respect to particular recommended candidates. The nominations and governance committee endeavors to identify director nominees who have the highest personal and professional integrity, have demonstrated exceptional ability and judgment, and, together with other director nominees and members, are expected to serve the long term interest of our stockholders and contribute to our overall corporate goals.
A copy of the nominations and governance committee’s written charter is publicly available through the “Investors-Governance” section of our website at www.catasys.com.
Compensation committee
The compensation committee currently consists of three directors Messrs. Sherman, Zecchini, and Giraldo, who are independent as defined by the NASDAQ rules. Mr. Giraldo was appointed to serve as a member of the Compensation Committee in November 2019. During 2019, the compensation committee held three meetings. Mr. Sherman serves as the chairman of the compensation committee. The compensation committee reviews and recommends to the board of directors for approval and compensation of our executive officers.
A copy of our compensation committee written charter is publicly available through the “Investors-Governance” section of our website at www.catasys.com.
Executive Officers
The following sets forth information regarding Mr. Christopher Shirley, a non-director and our former Chief Financial Officer, Mr. Richard A. Anderson, our former President and Chief Operating Officer, Mr. Curtis Medeiros, our current President and Chief Operating Officer, and Mr. Brandon H. LaVerne, our newly appointed Chief Financial Officer as of the date of this 10-K/A. For information regarding Terren S. Peizer, our Chief Executive Officer and Chairman, see “Director, Executive Officers and Corporate Governance” above.
Christopher Shirley has served as the Company’s Chief Financial Officer sincefrom May 2017 andto March 2020. He joined the Company with approximately 20 years of finance experience, including senior leadership roles at healthcare technology and big data companies. Most recently, Mr. Shirley served as the Chief Financial Officer of Sentient Science Corporation from September 2016 until February 2017. Previously, as CFO of GE Intelligent Platforms from March 2015 until September 2016, he led the finance function during a period of rapid expansion. Prior to joining GE Digital, from March 2014 until March 2015, Mr. Shirley was the Financial Integration Leader for GE Healthcare, where he led the financial integration and delivery of deal model expectations following its acquisition of API Healthcare. Before his role as Financial Integration Leader for GE Healthcare, Mr. Shirley served as Global Finance Manager of GE Healthcare beginning in June 2011. Mr. Shirley obtained his BS in finance from DePaul University in 1999.
Richard A. Berman Anderson served as a member of our management team from April 2005 to December 2019, and previously served as a director from July 2003 to November 2018. He served as our President and Chief Operating Officer since July 2008; in this role he was primarily responsible for the creation and leadership of our OnTrak solution. He has more than twenty-five years of experience in business development, strategic planning, operations, finance and management, with more than 15 years of that in the healthcare field. Prior to joining the Company, he held senior level financial and operational positions in healthcare and financial companies, and served as a director in PriceWaterhouseCoopers LLP’s business assurance and transaction support practices. He received a B.A. in Business Economics from University of California, Santa Barbara.
Mr. Curtis Medeiroshas served as our President and Chief Operating Officer since December 2019. Prior to joining the Company’s directorCompany, Mr. Medeiros was the President at OPTUM Analytics overseeing a group that served the analytical needs of external payers, providers and life sciences companies since 2014. HeisJuly 2019. Mr. Medeiros was the AssociatePresident of OPTUM Life Sciences at UnitedHealth Group from 2014 to April 2016, where he focused on creating novel collaboration opportunities that addressed health system challenges. From June 2014 to April 2016, Mr. Medeiros was the Chief Operating Officer and Senior Vice President of Strategic initiatives forat OPTUM Life Sciences where he led the University of South Florida ResearchOPTUM Life Sciences business, which drives client value by providing best in class real-world data, analytics, consulting and Innovation, visiting professor of social entrepreneurship incollaborations aimed at improving the Muma College of Business, and a professor in the institute of innovation and advanced discovery. As a recognized global leader, Mr. Berman has held positions in health care education, politics and management. He has worked with several foreign governments, the United Nations, the U.S. Department of Health and Welfare, the FDA, andsystem for all stakeholders. Prior to joining OPTUM in June 2010, Mr. Medeiros served as a cabinet level official for the state of New York. He has also worked with McKinsey & Co, NYU Medical Center, Westchester Medical, Korn-Ferry International, Howe-Lewis InternationalSenior Director at Merck Research Laboratories from January 2009 to May 2010. Mr. Medeiros holds a bachelor’s degree in Chemical Engineering from MIT and numerous startup companies. In 1995, Mr. Berman was selected by Manhattanville College to serve as its tenth President. Mr. Berman is credited with the turnaround of the College, where he served until 2009. Mr. Berman serves on the board of several organizations and is an elected member of the National Academy of Medicine of the National Academy of Sciences (Formerly known as the Institute of Medicine). Mr. Berman received his BBA, MBA and MPH from the University of Michigan and holds honorary doctorates from Manhattanville College and New York Medical College.
We believe Mr. Berman’s qualifications to serve on our board of directors include his extensive experience as an executive in several healthcare firms. In addition, as a board member of a health plan we believe he has an understanding of our customer base and current developments and strategies in the health insurance industry.Harvard Business School.
Richard J. BermanBrandon H. LaVerne has served as the Company’s directorChief Financial Officer since 2017. He was Chairman of National Investment Managers, a company with $12 billion pension administration assets from 2006-2011. Mr. Berman is a director of two other public healthcare companies: Advaxis, Inc. and Cryoport Inc. From 1998-2000, he was employed by Internet Commerce Corporation (now Easylink Services) as Chairman and CEO, and was a director from 1998-2012. Previously, Mr. Berman was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; created the largest battery company in the world in the 1980’s by merging Prestolite, General Battery and Exide and advised on over $4 billion of M&A transactions (completed over 300 deals). He is a past Director of the Stern School of Business of NYU where he obtained his BS and MBA. He also has US and foreign law degrees from Boston College and The Hague Academy of International Law, respectively.
We believe Mr. Berman’s qualifications to serve on our board of directors include his experience in the healthcare industry, and his current and past experience in numerous private and publicly traded companies.
Michael Sherman has served as the Company’s director since July 2017. He has worked in finance for over 30 years, having last served as a Managing Director in Investment Banking, at Barclays Plc.March 2020. Prior to Barclays,joining the Company, Mr. Sherman wasLaVerne worked at Lehman Brothers, Inc. and Salomon Brothers Inc. Mr. Sherman specialized in equity capital markets and covered Healthcare companies, in addition to companies in other sectors. Mr. Sherman also is currently a Board Member at BioVie, Inc., a specialty pharmaceutical company. Mr. Sherman began his career in finance as a lawyer at Cleary, Gottlieb, Steen & Hamilton in New York City and Hong Kong.
We believe that Mr. Sherman’s qualifications to serve on our board of directors include his experience in the banking and securities industry, and his experience in the healthcare industry.
Edward J. Zecchini has served as the Company’s director since October 2018. Heserves as the Chief Information Officer for Remedy Partners, Inc. since April 2014.Prior to that, Mr. Zecchini served as Executive Vice President and Chief Technology Officer at Sandata Technologies, LLC, from May 2010 to March 2014, President and Chief Executive Officer of IT Analytics LLC from March 2008 to April 2010, Executive Vice President of Operations and Chief Information Officer of Touchstone Healthcare Partnership from May 2007 to February 2008 and Senior Vice President and Chief Information Officer of HealthMarkets,PCM, Inc. from October 20041998 until its sale in August 2019 and most recently served as its Chief Financial Officer, Chief Accounting Officer, Treasurer and Assistant Secretary since July 2007. Prior to April 2007. Earlier injoining PCM, Inc. Mr. LaVerne worked as the Corporate Accounting Supervisor for Computer Sciences Corporation from September 1996 to October 1998, and started his career he held senior level positions at Thomson Healthcare and SportsTicker, Inc.with Deloitte & Touche LLP in September 1993. Mr. Zecchini has over thirty years of experience in the healthcare and information technology industries. Mr. Zecchini holds aLaVerne received his Bachelor of Arts degree from the State University of New York at Oswego. Mr. Zecchini’s business expertise, including his background and extensive experience information technology and management makes him well-qualified to serve as a member of the board of directors. He is also a Director of Cryoport Inc. Mr. Zecchini became a member of the Cryoport, Inc. (NASDAQ: symbol “CYRX.”) board of directorsScience in September 2013 and serves as Chairman of the Compensation Committee and member of the Audit Committee and Scientific and Technology Committee.
We believe Mr. Zecchini’s qualifications to serve on our board of directors include his experience in the healthcare industry, and his current and past experience in numerous private and publicly traded companies.
Sharon R. Gabrielson has served as the Company’s director since October 2018. She serves as Chair of the Mayo Clinic’s Global Business Solutions Department where she directs domestic and international opportunities for commercializing the Clinic’s products in BSB and B2C markets since March 2015, and from July 2010 to March 2015, she served as the Vice Chair of Mayo Clinic Health System. She began her career as a registered nurse and has 35 years of experience as a health care executive. She has extensive knowledge of technology, operations, strategic planning, governance, and business development. Ms. Gabrielson serves on the board of directors for Sharps Compliance, Inc. (Medical Waste), on the nurse executive advisory board of Strategic Partners, Inc. (Medical Uniforms), and is an advisor to CyberMDX (Medical Device Cybersecurity). She has also served on several nonprofit boards. She earned her bachelor’s degree from Winona State University, Minnesota and her masters degree from Saint Mary’s University, Minnesota in Management Health Care Administration in 2000.
We believe Mrs. Gabrielsons’s qualifications to serve on our board of directors include her experience in the healthcare industry, her extensive technology, finance, human resources, insurance, business development experience and her current and past experience in numerous private companies.
Diane Seloff has served as the Company’s director since October 2018. She has served as Chief Operating Officer at Aspire Health where she has been part of the founding leadership team since October 2013. As Aspire Health’s Chief Operating Officer, Ms. Seloff built all the corporate functions for the company in its first two years and is responsible for running and transforming Aspire Health’s operations. She previously held senior executive roles in operations and development at other healthcare services and technology companies, including Vanderbilt University Medical Center from October 2007 to July 2013. Ms. Seloff began her career as a management consultant—first at Arthur Andersen & Company and later at KPMG Peat Marwick. Ms. Diane Seloff possesses over 25 years of experience in the broader healthcare industry and has diverse experience in operations, human capital, finance, technology, strategic planning and business development in healthcare, financial services, and logistics. Ms. Seloff received her MBA from Columbia University in 1990 and received her BS in EngineeringAccounting from University of Michigan in 1984.Southern California and is a Certified Public Accountant.
We believe Mrs. Seloff’s qualificationsCode of Ethics
Our Board of Directors has adopted a code of ethics applicable to serveour chief executive officer, chief financial officer and persons performing similar functions. Our code of ethics is accessible on our boardwebsite at http://www.catasys.com. Disclosure regarding any amendments to, or waivers from, provisions of directors include her extensive experience as an executivethe code of ethics will be included in several healthcare firms. In addition, as a board member we believe she has an understandingCurrent Report on Form 8-K within four business days following the date of our customer base and current developments and strategies in the health insurance industry.amendment or waiver.
Delinquent Section 16(a) beneficial ownership reporting complianceReports
Section 16(a) of the Securities Exchange Act of 1934, as amended (Exchange Act), requires our directors and executive officers, and persons who own more than 10% of our outstanding common stock, to file with the SEC, initial reports of ownership and reports of changes in ownership of our equity securities. Such persons are required by SEC regulations to furnish us with copies of all such reports they file.
To our knowledge, based solely on a review of the copies of such reports furnished to us regarding the filing of required reports, we believe that all Section 16(a) reports applicable to our directors, executive officers and greater-than-ten-percent beneficial owners with respect to fiscal 20182019 were timely filed, except that an initial report of ownership was filed late by Mr. ZecchiniMessrs. Rebak, Giraldo and Mses. Seloff and Gabrielson.Medeiros.
Anti-Hedging Policy
We have adopted an insider trading policy that includes a provision restricting trading of any interest or provision relating to the future price of our securities, such as a put, call or short sale.
Code of Ethics
Our Board of Directors has adopted a code of ethics applicable to our chief executive officer, chief financial officer and persons performing similar functions. Our code of ethics is listed hereto as Exhibit 14.1 and is accessible on our website at http://www.catasys.com. Disclosure regarding any amendments to, or waivers from, provisions of the code of ethics will be included in a Current Report on Form 8-K within four business days following the date of the amendment or waiver.
Independence of the Board of Directors
Our common stock is traded on the NASDAQ Capital Market. The Board of Directors has determined that six of the members of the Board of Directors qualify as “independent,” as defined by the listing standards of the NASDAQ. Consistent with these considerations, after review of all relevant transactions and relationships between each director, or any of his family members, and the Company, its senior management and its independent auditors, the Board has determined further that Messrs. and Mses. Berman, Berman, Sherman, Zecchini, Gabrielson and Seloff are independent under the listing standards of NASDAQ. In making this determination, the Board of Directors considered that there were no new transactions or relationships between its current independent directors and the Company, its senior management and its independent auditors since last making this determination.
Committees of the Board of Directors
Audit committee
Our audit committee currently consists of three directors, Mr. Richard A. Berman, Mr. Richard J. Berman and Ms. Diane Seloff with Mr. Richard A. Berman serving as the chairman of the audit committee. The audit committee had five meetings during the 2018 year. The Board of Directors has determined that each of the members of the audit committee were independent as defined by the NASDAQ rules, meet the applicable requirements for audit committee members, including Rule 10A-3(b) under the Exchange Act, and that Mr. Richard A. Berman qualifies as an “audit committee financial expert” as defined by Item 401(h)(2) of Regulation S-K. The duties and responsibilities of the audit committee include (i) selecting, evaluating and, if appropriate, replacing our independent registered accounting firm, (ii) reviewing the plan and scope of audits, (iii) reviewing our significant accounting policies, any significant deficiencies in the design or operation of internal controls or material weakness therein and any significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation and (iv) overseeing related auditing matters.
A copy of the audit committee’s written charter is publicly available through the “Investors-Governance” section of our website at www.catasys.com.
Nominations and governance committee
Our nominations and governance committee currently consists of three members Messrs. Sherman, Berman and Mses. Gabrielson, who are all independent as defined by the NASDAQ rules. The nominations and corporate governance committee had two meetings during 2018. Mr. Sherman serves as the chairman of the nominations and corporate governance committee. The committee nominates new directors and periodically oversees corporate governance matters.
The charter of the nominations and governance committee provides that the committee will consider board candidates recommended for consideration by our stockholders, provided the stockholders provide information regarding candidates as required by the charter or reasonably requested by us within the timeframe proscribed in Rule 14a-8 of Regulation 14A under the Exchange Act, and other applicable rules and regulations. Recommendation materials are required to be sent to the nominations and governance committee c/o Catasys, Inc., 11601 Wilshire Boulevard, Suite 1100, Los Angeles, California 90025. There are no specific minimum qualifications required to be met by a director nominee recommended for a position on the board of directors, nor are there any specific qualities or skills that are necessary for one or more of our directors to possess, other than as are necessary to meet any requirements under the rules and regulations applicable to us. The nominations and governance committee considers a potential candidate's experience, areas of expertise, and other factors relative to the overall composition of the board of directors.
The nominations and governance committee considers director candidates that are suggested by members of the board of directors, as well as management and stockholders. Although it has not been previously utilized, the committee may also retain a third-party executive search firm to identify candidates. The process for identifying and evaluating nominees for director, including nominees recommended by stockholders, involves reviewing potentially eligible candidates, conducting background and reference checks, interviews with the candidate and others (as schedules permit), a meeting to consider and approve the candidate and, as appropriate, preparing and presenting to the full board of directors an analysis with respect to particular recommended candidates. The nominations and governance committee endeavors to identify director nominees who have the highest personal and professional integrity, have demonstrated exceptional ability and judgment, and, together with other director nominees and members, are expected to serve the long term interest of our stockholders and contribute to our overall corporate goals.
A copy of the nominations and governance committee’s written charter is publicly available through the “Investors-Governance” section of our website at www.catasys.com.
Compensation committee
The compensation committee currently consists of three directors Messrs. Michael Sherman, Richard J. Berman, and Edward Zecchini, who are independent as defined by the NASDAQ rules. During 2018, the compensation committee held three meetings. Mr. Sherman serves as the chairman of the compensation committee. The compensation committee reviews and recommends to the board of directors for approval and compensation of our executive officers.
A copy of our compensation committee written charter is publicly available through the “Investors-Governance” section of our website at www.catasys.com.
| ITEM 11. EXECUTIVE COMPENSATION |
Summary Compensation Table
The following table sets forth the total compensation paid during the last two fiscal years ended December 31, 20182019 and 20172018 to (1) our Chief Executive Officer, and (2) our two next most highly compensated executive officers who earned more than $100,000 during the fiscal year ended December 31, 20182019 and were serving as executive officers as of such date.date, and (3) our former President and Chief Operating Officer, who would have qualified pursuant to foregoing clause (2) except that he was not serving as an executive officer as of December 31, 2019.
All | ||||||||||||||||||||||||||||||||||||||||||||||
Other | All | |||||||||||||||||||||||||||||||||||||||||||||
Compen- | Other | |||||||||||||||||||||||||||||||||||||||||||||
Name and | Stock/Option | sation ($) | Compen- | |||||||||||||||||||||||||||||||||||||||||||
Principal Position | Year | Salary ($) | Bonus ($) | Award ($) | (4) | Total ($) | Year | Salary ($) | Bonus ($) | Stock/Option Award ($) | sation ($) (4) | Total ($) | ||||||||||||||||||||||||||||||||||
Terren S. Peizer, | 2018 | 450,000 | - | 1,946,309 | 15,497 | 2,411,806 | 2019 | 450,000 | - | - | 13,233 | 463,233 | ||||||||||||||||||||||||||||||||||
Chairman and | 2017 | 450,000 | (1) | - | 1,900,000 | 15,064 | 2,365,064 | (1) | 2018 | 450,000 | - | 1,946,309 | 15,497 | 2,411,806 | ||||||||||||||||||||||||||||||||
Chief Executive Officer | ||||||||||||||||||||||||||||||||||||||||||||||
Richard A. Anderson, | 2018 | 408,205 | - | 868,858 | 27,884 | 1,304,947 | 2019 | 421,278 | - | 2,659,036 | 34,367 | 3,114,681 | ||||||||||||||||||||||||||||||||||
President and | 2017 | 444,251 | (2) | - | - | 26,009 | 470,260 | |||||||||||||||||||||||||||||||||||||||
Chief Operating Officer | ||||||||||||||||||||||||||||||||||||||||||||||
Former President and | 2018 | 408,205 | - | 868,858 | 27,884 | 1,304,947 | ||||||||||||||||||||||||||||||||||||||||
Chief Operating Officer(1) | ||||||||||||||||||||||||||||||||||||||||||||||
Curtis Medeiros | 2019 | 16,346 | - | 3,706,661 | - | 3,723,007 | ||||||||||||||||||||||||||||||||||||||||
President and Chief Operating Officer (2) | 2018 | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
Christopher Shirley, | 2018 | 285,000 | 15,000 | - | 16,013 | 316,013 | 2019 | 285,000 | - | 851,615 | 17,940 | 1,154,555 | ||||||||||||||||||||||||||||||||||
Chief Financial | 2017 | 168,808 | (3) | - | 409,000 | 26,085 | 603,893 | 2018 | 285,000 | 15,000 | - | 16,013 | 316,013 | |||||||||||||||||||||||||||||||||
Officer | ||||||||||||||||||||||||||||||||||||||||||||||
Officer (3) | ||||||||||||||||||||||||||||||||||||||||||||||
(1) | Mr. |
(2) |
|
(3) | Mr. Shirley |
(4) | Includes group medical and dental benefits, group life insurance premiums, accidental death, long-term disability insurance and |
Narrative Disclosures to Summary Compensation Table
Executive employment agreements
Chief Executive OfficerExecutive Officer
We entered into a five-year employment agreement with our Chairman and Chief Executive Officer, Terren S. Peizer, effective as of September 29, 2003, which automatically renews after each five-year term. Mr. Peizer received an annual base salary of $450,000 in each of 20182019 and 2017, part of which was deferred for the 2017 year and paid in common stock in April 2017.2018. Mr. Peizer is also eligible for an annual bonus targeted at 100% of his base salary based on goals and milestones established and reevaluated on an annual basis by mutual agreement between Mr. Peizer and the Board of Directors. Mr. Peizer did not receive any annual bonus during the fiscal years ended December 31, 20182019 and 2017.2018. His base salary and bonus target will be adjusted each year to not be less than the median compensation of similarly positioned CEO’s of similarly situated companies. Mr. Peizer receives executive benefits including group medical and dental insurance, term life insurance equal to 150% of his salary, accidental death and long-term disability insurance, grossed up for taxes. Mr. Peizer was not granted 397,693any equity awards during 20182019 and 642,307was granted 397,693 equity awards during 2018. All unvested options vest immediately in the event of a change in control, termination without good cause or resignation with good reason. In the event that Mr. Peizer is terminated without good cause or resigns with good reason prior to the end of the term, he will receive a lump sum payment equal to the remainder of his base salary and targeted bonus for the year of termination, plus three years of additional salary, bonuses and benefits. If any of the provisions above result in an excise tax, we will make an additional “gross up” payment to eliminate the impact of the tax on Mr. Peizer.
President and Chief Operating Officer
We entered into a three-year employment agreement with Mr. Medeiros dated November 15, 2019 and commencing on December 2, 2019 (the “Commencement Date”), with an option to renew for an additional three-year term unless terminated by either party within 90 days of the end of the original term. Mr. Medeiros received an annual base salary of $16,346 in 2019. Mr. Medeiros was eligible for an annual bonus targeted at 100% of his base salary based on achieving certain milestones. Mr. Medeiros did not receive any annual bonus during the fiscal period ended December 31, 2019. Mr. Medeiros received executive benefits, including group medical and dental insurance, term life insurance, accidental death and long-term disability insurance. Mr. Medeiros was granted 300,000 equity awards during 2019 and a common stock grant valued at $400,000 based upon the closing price of our stock on his Commencement Date. All unvested options vest immediately in the event of a change in control. In the event that Mr. Medeiros is terminated without good cause the option will continue to vest for a period of twelve months following the date of termination. In the event that Mr. Medeiros is terminated without good cause or resigns with good reason prior to the end of the term, on the six month anniversary of his termination he will receive a lump sum payment equal to twelve months base salary plus a pro-rata share of any bonus earned for the year of termination.
Former President and Chief Operating OfficerChief Operating Officer
We entered into a four-year employment agreement with our former President and Chief Operating Officer, Richard A. Anderson, effective April 19, 2005, as amended on July 16, 2008, as amended as of December 30, 2008 and as amended on April 10, 2018. The April 10, 2018 amendment to his employment agreement withhas a five-year term, and automatically renews for additional three-year terms unless otherwise terminated. Mr. Anderson’s agreement renewed for an additional three-year term in April 2018. Mr. Anderson received an annual base salary of $421,278 in 2019 and $408,205 in 2018 and $394,251 in 2017.2018. Mr. Anderson received a vacation payout of $50,000 in 2017. Mr. Anderson iswas eligible for an annual bonus targeted at 50% of his base salary based on achieving certain milestones. Mr. Anderson did not receive any annual bonus during the fiscal years ended December 31, 20182019 and 2017.2018. Mr. Anderson’s compensation will bewas adjusted each year by an amount not less than the Consumer Price Index. Mr. Anderson received executive benefits, including group medical and dental insurance, term life insurance, accidental death and long-term disability insurance. Mr. Anderson was not granted any equity awards during 2019 and granted 1,040,000 equity awards during 20182018. Mr. Anderson resigned from his position as the President and no equity awards during 2017. InChief Operating Officer of the eventCompany on December 2, 2019. As part of termination or resignation without good causehis separation agreement, Mr. Anderson continued as a Special Advisor to the Company, with a transition period beginning December 2, 2019 and without achieving any applicable performance targets duringending one-year from this date (the “Transition Period”). During the fiscal year in which such involuntary termination or resignation occurred,Transition Period, Mr. Anderson will receive forty present (40%)(1) the equivalent of any options that have vested. Mr. Anderson will receive sixty present (60%) of any options that have vested in the event of termination or resign without good cause and achieving any applicable performance targets during the fiscal year in which such involuntary termination or resignation occurred. In the event of termination without good cause or resignation with good reason prior to the end of the term, upon execution of a mutual general release, Mr. Anderson will receive a lump sum payment equal tohis one year of salary and bonus equal to 50% of that yearyear’s base salary, and will receivepayable in equal installments consistent with the Company’s regular payroll cycle; (2) existing health benefits continued medical benefits for one year unless hethrough December 2, 2020 or until such time as Mr. Anderson becomes eligible for coveragesimilar benefits through another employer; (3) 115,950 of his stock options previously granted under another employer's plan. If he is terminated without cause or resigns with good reason within twelve months followingour 2017 stock incentive plan which shall immediately vest, and (4) a change in control, upon executionvacation payout of a general release he will receive a lump sum payment equal to one and one-half years of salary, 150%$48,000 payable at the conclusion of the targeted bonus,Transition Period. On December 30, 2019, Mr. Anderson exercised his right to cease providing services to the Company under his separation agreement and will receive continued medical benefits for 18 months unless he becomes eligible for coveragecontinue receiving severance according to the terms listed under another employer's plan. the Transition Period.
Former Chief Financial OfficerFinancial Officer
We entered into a two-year employment agreement with Mr. Shirley effective May 31, 2017. After the initial two-year term, the employment agreement2017, which automatically renews for an additional two-year term unless terminated by either party within 90 days of the end of the initial term. Mr. Shirley’s employment agreement was amended on December 16, 2019, pursuant to which Mr. Shirley’s base salary was increased from $285,000 to $345,000 annually, and Mr. Shirley was entitled to receive a qualified incentive stock option to purchase 65,000 shares of common stock under and subject to all the provisions of the Company’s 2017 Stock Incentive Plan. Mr. Shirley received an annual base salary of $285,000 in 20182019 and a pro-rated annual base salary of $168,808$285,000 in 2017,2018, and is eligible for a bonus targeted at 40% of his base salary based on achieving certain milestones. Mr. Shirley did not receive any annual bonus during the fiscal year ended December 31, 2019 and received a guaranteed bonus of $15,000 during the 2018 year. Mr. Shirley was granted 135,00065,000 equity awards during 20172019 and no equity awards during 2018.
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
The following table sets forth all outstanding equity awards held by our named executive officers as of December 31, 2018.2019.
Number of | |||||||||||||
Number of | Securities | ||||||||||||
Securities | Underlying | ||||||||||||
Underlying | Unexercised | Option | |||||||||||
Unexercised | Options (#) | Exercise | Option | ||||||||||
Options (#) | Unexer- | Price | Expiration | ||||||||||
Name | Exercisable | cisable | ($) | Date | |||||||||
Terren S. Peizer | 400 | - | 1,161.60 | 10/27/19 | |||||||||
| 24,750 | - | 105.60 | 12/06/20 | ||||||||||
| - | 642,307 | 7.50 | 01/01/23 | ||||||||||
| - | 397,693 | 7.50 | 01/01/23 | ||||||||||
| 25,150 | 1,040,000 | ||||||||||||
Richard A. Anderson | 208 | - | 1,056.00 | 10/27/19 | |||||||||
| 24,750 | - | 96.00 | 12/06/20 | ||||||||||
| - | 642,307 | 7.50 | 04/10/28 | ||||||||||
| - | 397,693 | 7.50 | 08/02/28 | ||||||||||
| 24,958 | 1,040,000 | ||||||||||||
Christopher Shirley | 33,750 | 101,250 | 7.50 | 12/19/27 | |||||||||
Number of | |||||||||||||
Number of | Securities | ||||||||||||
Securities | Underlying | ||||||||||||
Underlying | Unexercised | Option | |||||||||||
Unexercised | Options (#) | Exercise | Option | ||||||||||
Options (#) | Unexer- | Price | Expiration | ||||||||||
Name | Exercisable | cisable | ($) | Date | |||||||||
Terren S. Peizer | 24,750 | - | 105.60 | 12/09/20 | |||||||||
| - | 642,307 | (1) | 7.50 | 12/19/27 | |||||||||
| - | 397,693 | (1) | 7.50 | 08/02/28 | |||||||||
| 24,750 | 1,040,000 | ||||||||||||
Richard A. Anderson | 115,950 | - | (2) | 7.50 | 03/29/20 | ||||||||
Curtis Medeiros | - | 300,000 | (3) | 15.55 | 12/02/29 | ||||||||
Christopher Shirley (4) | 67,500 | 67,500 | (5) | 7.50 | 12/19/27 | ||||||||
| 2,600 | 62,400 | (6) | 16.48 | 12/16/29 | |||||||||
| 70,100 | 129,900 | ||||||||||||
(1) | Mr. Peizer’s options shall vest on January 1, 2023, if the Volume Weighted Average Price of our common stock is $15.00 for at least twenty trading days within a period of thirty consecutive trading days ending on the trading day prior to January 1, 2023. | |
(2) |
| |
(3) | One third of Mr. Medeiros stock options vest one-year from grant date and the remaining stock options vest equally over the next 24 months. | |
(4) | Mr. Shirley resigned from his position as the Chief Financial Officer of the Company effective March 16, 2020. | |
(5) | One quarter of Mr. Shirley’s stock options | |
(6) | 2,600 of Mr. Shirley’s stock options shall vest on each of 25 equal monthly installments beginning on December 19, | |
POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE-IN-CONTROL
Potential payments upon termination
The following summarizes the payments that the named executive officers would have received if their employment had terminated on December 31, 2018.2019.
If Mr. Peizer's employment had terminated due to disability, he would have received insurance and other fringe benefits for a period of one year thereafter, with a value equal to approximately $11,000.$10,000. If Mr. Peizer had been terminated without good cause or resigned for good reason, he would have received a lump sum payment of $2,734,000,$2,729,000, based upon: (i) three years of additional salary at $450,000 per year; (ii) three years of additional bonus of $450,000 per year; and (iii) three years of fringe benefits, with a value equal to approximately $34,000.$29,000.
If Mr. AndersonMedeiros had been or is terminated without good cause, or resigned for good reason, he would have received a lump sum payment of approximately $612,000 based upon one year's salary plus the full targeted bonus of 50% of base salary. In addition, medical benefits would continue for up$425,000, equal to one year withof salary, payable on the six month anniversary of his termination plus a value equal to approximately $24,000.pro-rata share of any bonus earned for the year of termination.
If Mr. Shirley had been or is terminated without good cause, or resigned for good reason, he would have received a lump sum payment of approximately $142,500 an amount$172,500, equal to six months’ salary, plus a pro-rata share of any bonus earned in the year of termination.
Potential payments upon change in control
Upon a change in control, the unvested stock options of each of our named executive officers would have vested, with the values set forth above.
If Mr. Peizer had been terminated without good cause or resigned for good reason within twelve months following a change in control, he would have received a lump sum payment of $2,734,000,$2,729,000, as described above, plus a tax gross up of approximately $683,000.
If Mr. Anderson had been terminated without good cause or resigned for good reason within twelve months following a change in control, he would have received a lump sum payment of approximately $918,000, based upon one-and-a-half year's salary plus one-and-a-half the full targeted bonus of 50% of base salary. In addition, medical benefits would continue for up to one-and-a-half years, with a value equal to approximately $36,000.$682,000.
DIRECTOR COMPENSATION
The following table provides information regarding compensation that was earned or paid to the individuals who served as non-employee directors during the year ended December 31, 2018.2019. Except as set forth in the table, during 2018,2019, directors did not earn nor receive cash compensation or compensation in the form of stock awards, option awards or any other form.
Option | Option | |||||||||||||||
Name | awards ($) | Total | awards ($) | Total ($) | ||||||||||||
Richard A. Berman | 131,585 | 131,585 | 91,671 | 91,671 | ||||||||||||
Richard J. Berman | 102,468 | 102,468 | 33,873 | 33,873 | ||||||||||||
Michael Sherman | 123,669 | 123,669 | 83,609 | 83,609 | ||||||||||||
Edward J. Zecchini | 43,958 | 43,958 | 290,780 | 290,780 | ||||||||||||
Sharon R. Gabrielson | 43,958 | 43,958 | 175,815 | 175,815 | ||||||||||||
Diane Seloff | 39,462 | 39,462 | 272,798 | 272,798 | ||||||||||||
Robert Rebak (3) | 186,287 | 186,287 | ||||||||||||||
Gustavo A. Giraldo (4) | - | - | ||||||||||||||
(1) Mr. Berman resigned from his position as a director of the Company on July 16, 2019.
(2) Ms. Gabrielson resigned from her position as a director of the Company on November 15, 2019.
(3) Mr. Rebak was appointed to serve as a member of our board of directors in July 2019.
(4) Mr. Giraldo was appointed to serve as a member of our board of directors in November 2019.
Notes to director compensation table:
Amounts reflect the compensation expense recognized in the Company's financial statements in 2019 for non-employee director stock options, in accordance with FASB ASC Topic 718. As such, these amounts do not correspond to the compensation actually realized by each director for the period. |
|
Outstanding equity awards held by non-employee directors as of December 31, 2018,2019, were as follows:
Aggregate | Aggregate | |||||||||||||||
grant date | grant date | |||||||||||||||
Options | fair market value | Options | fair market value | |||||||||||||
outstanding | options | outstanding | options | |||||||||||||
(#) | outstanding ($) | (#) | outstanding ($) | |||||||||||||
Richard A. Berman | 150,032 | $ | 231,865 | 150,032 | $ | 777,513 | ||||||||||
Richard J. Berman | 80,083 | 171,354 | 25,172 | 98,950 | ||||||||||||
Michael Sherman | 98,834 | 211,474 | 98,834 | 250,826 | ||||||||||||
Edward J. Zecchini | 35,647 | 219,773 | 85,551 | 535,927 | ||||||||||||
Sharon R. Gabrielson | 35,647 | 219,773 | 35,647 | 219,773 | ||||||||||||
Diane Seloff | 35,647 | 197,295 | 85,551 | 513,449 | ||||||||||||
Robert Rebak (3) | 85,551 | 1,117,722 | ||||||||||||||
Gustavo A. Giraldo (4) | 8,360 | 79,576 | ||||||||||||||
| 435,890 | $ | 1,251,534 | 574,698 | $ | 3,593,736 | |||||||||||
(1) Mr. J. Berman resigned from his position as a director of the Company on July 16, 2019.
(2) Ms. Gabrielson resigned from her position as a director of the Company on November 15, 2019.
(3) Mr. Rebak was appointed to serve as a member of our board of directors in July 2019.
(4) Mr. Giraldo was appointed to serve as a member of our board of directors in November 2019.
There were a total of 435,890574,698 stock options outstanding to directors as of December 31, 2018,2019, with an aggregate grant date fair value of $1,251,534,$3.6 million, the last of which vest in December 2019.June 2022. There were 293,623 options granted to non-employees during 2019 and 235,081 options granted to non-employees during 2018 and 332,557 options granted to non-employee directors during 2017.2018.
EQUITY COMPENSATION PLAN INFORMATION
The following table provides certain aggregate information with respect to all of the Company’s equity compensation plans in effect as of December 31, 2018.2019.
Plan Category | a(a) Number of securities to be issued upon exercise of outstanding options, warrants and right |
a(b) Weighted-average exercise price of outstanding options, warrants and rights | a(c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | |||||||||
Equity compensation plans approved by security holders (1) | 3,761,278 | $ | 9.44 | 215,909 | ||||||||
Equity compensation plans not approved by security holders | - | - | - | |||||||||
Total | 3,761,278 | $ | 9.44 | 215,909 | ||||||||
Plan Category | (a) Number of securities to be issued upon exercise of outstanding options, warrants and right |
(b) Weighted-average exercise price of outstanding options, warrants and rights | (c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | |||||||||
Equity compensation plans approved by security holders (1) | 4,006,351 | $ | 10.92 | 325,162 | ||||||||
Equity compensation plans not approved by security holders | - | - | - | |||||||||
Total | 4,006,351 | $ | 10.92 | 325,162 | ||||||||
(1) We adopted our 2017 Stock Incentive Plan (the “2017 Plan”) in 2017. In August 2018, stockholders approved an amendment to the 2017 Plan to provide for an additional 1,400,000 shares to be issued in connection with awards granted thereunder (the “2017 Amended Plan”). Under the 2017 Amended Plan, we can grant incentive stock options, non-qualified stock option, restricted and unrestricted stock awards and other stock-based awards. As of December 31, 2018, 215,9092019, 325,162 equity awards remained reserved for future issuance under the 2017 Plan.
Compensation Committee Interlocks and Insider Participation
Currently, our Compensation Committee consists of Messrs. Michael Sherman, Edward Zecchini, and Gustavo A. Giraldo. No current or expected member of the Compensation Committee, nor any of our Named Executive Officers, has a relationship that would constitute an interlocking relationship with executive officers or directors of another entity.
No current or expected member of our Compensation Committee is or has been an officer or employee of the Company. None of our executive officers currently serves, or in the past year has served, as a member of the Board or Compensation Committee (or other Board committee performing equivalent functions) of any entity that has one or more of its executive officers serving on our Board or Compensation Committee.
ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
|
The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 19, 2019April 24, 2020 for (a) each stockholder known by us to own beneficially more than 5% of our common stock (b) our named executive officers, (c) each of our directors, and (d) all of our current directors and executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of March 19, 2019April 24, 2020 pursuant to the exercise of options or warrants to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 16,205,14616,982,992 shares of common stock outstanding on March 19, 2019.April 24, 2020.
Total | ||||||||||||||||
Shares | common | |||||||||||||||
Common | beneficially | stock | Percent | |||||||||||||
stock | owned | beneficially | of | |||||||||||||
Name of beneficial owner (1) | owned (2) | (3) | owned | class (3) | ||||||||||||
Directors and Named Executive Officers: | ||||||||||||||||
Terren S. Peizer (4) | 9,193,041 | 1,274,339 | 10,467,380 | 59.9 | % | |||||||||||
Richard A. Anderson (5) | - | 24,958 | 24,958 | * | ||||||||||||
Christopher Shirley (6) | - | 47,813 | 47,813 | * | ||||||||||||
Richard A. Berman (7) | - | 81,274 | 81,274 | * | ||||||||||||
Richard J. Berman (8) | - | 58,695 | 58,695 | * | ||||||||||||
Michael Sherman (9) | 15,500 | 73,176 | 88,676 | * | ||||||||||||
Edward J. Zecchini (10) | - | 14,259 | 14,259 | * | ||||||||||||
Sharon R. Gabrielson (11) | - | 14,259 | 14,259 | * | ||||||||||||
Diane Seloff (12) | - | 14,259 | 14,259 | * | ||||||||||||
All directors and named executive officers as a group (9 persons) | 9,208,541 | 1,603,032 | 10,811,573 | 60.8 | % | |||||||||||
Total | ||||||||||||||||
Shares | common | |||||||||||||||
Common | beneficially | stock | Percent | |||||||||||||
stock | owned | beneficially | of | |||||||||||||
Name of beneficial owner (1) | owned (2) | (3) | owned | class (3) | ||||||||||||
Directors and Named Executive Officers: | ||||||||||||||||
Terren S. Peizer (4) | 9,119,155 | 1,273,939 | 10,393,094 | 56.9 | % | |||||||||||
Richard A. Berman (5) | - | 154,056 | 154,056 | * | ||||||||||||
Michael Sherman (6) | 15,550 | 102,992 | 118,542 | * | ||||||||||||
Edward J. Zecchini (7) | - | 42,776 | 42,776 | * | ||||||||||||
Diane Seloff (8) | - | 42,776 | 42,776 | * | ||||||||||||
Robert Rebak (9) | 8,200 | 21,388 | 29,588 | * | ||||||||||||
Gustavo Giraldo (10) | - | 3,550 | 3,550 | * | ||||||||||||
Curtis Medeiros (11) | 65,821 | - | 65,821 | * | ||||||||||||
Brandon H. LaVerne (12) | - | - | - | * | ||||||||||||
All directors, director nominee and named executive officers as a group (9 persons) | 9,208,726 | 1,641,477 | 10,850,203 | 58.3 | % | |||||||||||
* Less than 1% |
(1) | Except as set forth below, the mailing address of all individuals listed is c/o Catasys, Inc., |
(2) | The number of shares beneficially owned includes shares of common stock in which a person has sole or shared voting power and/or sole or shared investment power. Except as noted below, each person named reportedly has sole voting and investment powers with respect to the common stock beneficially owned by that person, subject to applicable community property and similar laws. |
(3) | On |
(4) | Consists of warrants to purchase 1,249,189 shares of common stock and options to purchase |
(5) | Includes options to purchase |
(6) |
|
(7) | Includes options to purchase |
(8) | Includes options to purchase |
(9) | Mr. Rebak was appointed to serve as a member of the Board on July 18, 2019. Consists of |
(10) | Mr. Giraldo was appointed to serve as a member of the Board on November 19, 2019. Includes options to purchase |
(11) |
|
(12) |
|
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
Review and Approval of Transactions with Related Persons
Either the audit committee or the Board of Directors approves all related party transactions. The procedure for the review, approval or ratification of related party transactions involves discussing the proposed transaction with management, discussing the proposed transaction with the external auditors, reviewing financial statements and related disclosures, and reviewing the details of major deals and transactions to ensure that they do not involve related party transactions. Members of management have been informed and understand that they are to bring related party transactions to the audit committee or the Board of Directors for pre-approval. These policies and procedures are evidenced in the audit committee charter and our code of ethics.
Certain Transactions
In January 2017, we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which the Company received aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 (the “January 2017 Convertible Debenture”) and (ii) five-year warrants to purchase shares of the Company’s common stock in an amount equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the “January 2017 Warrants”). In April 2017, the January 2017 Convertible Debenture principal and interest was paid in full with proceeds from our public offering.ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
|
|
The following table presents fees for professional audit services rendered by EisnerAmper LLP (“EisnerAmper”) for the audit of the Company’s annual financial statements for the year ended December 31, 20182019 and Rose, Snyder & Jacobs LLP for the audit of the Company’s annual financial statement for the year ended December 31, 2017,2018 and fees billed for other services rendered by EisnerAmper LLP and Rose, Synder & Jacobs LLP during those periods.
2018 | 2017 | 2019 | 2018 | |||||||||||||
Audit fees (1) | $ | 156,100 | $ | 139,500 | $ | 348,250 | $ | 156,100 | ||||||||
Audit-related fees | - | - | - | - | ||||||||||||
Tax fees: | - | - | - | - | ||||||||||||
All other fees: | - | 242 | - | - | ||||||||||||
Total | $ | 156,100 | $ | 139,742 | $ | 348,250 | $ | 156,100 | ||||||||
(1) Audit fees consisted of audit work performed in the preparation of financial statements, as well as work generally only the independent registered public accounting firm can reasonably be expected to provide, such as statutory audits.
Policy on Audit Committee Pre-Approval of Audit and Permissible Non-audit Services of Independent Public Accountant
Consistent with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and overseeing the work of our independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy to pre-approve all audit and permissible non-audit services provided by our independent registered public accounting firm.
Prior to engagement of an independent registered public accounting firm for the next year’s audit, management will submit an aggregate of services expected to be rendered during that year for each of four categories of services to the Audit Committee for approval.
1. Audit services include audit work performed in the preparation of financial statements, as well as work that generally only an independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards.
2. Audit-Related services are for assurance and related services that are traditionally performed by an independent registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.
3. Tax services include all services performed by an independent registered public accounting firm’s tax personnel except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice.
4. Other Fees are those associated with services not captured in the other categories. The Company generally does not request such services from our independent registered public accounting firm.
Prior to engagement, the Audit Committee pre-approves these services by category of service. The fees are budgeted and the Audit Committee requires our independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service. During the year, circumstances may arise when it may become necessary to engage our independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit Committee requires specific pre-approval before engaging our independent registered public accounting firm.
The Audit Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit Committee at its next scheduled meeting.
|
ITEM 15. EXHIBITS, FINANCIAL STATEMENT AND SCHEDULES
(a)(1),(2) Financial Statements
The Financial Statements and Financial Statement Schedules listed on page F-1 of this document are filed as part of this filing.
(a)(3) Exhibits
The following exhibits are filed as part of this report:
Exhibit No. | Description | |
| ||
| ||
| ||
3.6 | ||
| ||
| ||
|
| ||
| ||
| ||
4.2 | ||
| ||
| ||
| ||
4.3 | ||
4.4 | ||
4.5 | ||
4.6 | ||
10.1# | ||
10.2# | ||
| ||
| ||
|
| ||
| ||
|
| |
| Consent of Independent Registered Public Accounting Firm – EisnerAmper LLP. | |
31.1** | ||
31.2** | ||
31.3* | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to § 302 of the Sarbanes-Oxley Act of 2002. | |
31.4* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to § 302 of the Sarbanes-Oxley Act of 2002. | |
32.1** | ||
32.2** | ||
101.INS** | XBRL Instance Document | |
101.SCH** | XBRL Taxonomy Extension Schema Document | |
101.CAL** | XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF** | XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB** | XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE** | XBRL Taxonomy Extension Presentation Linkbase Document |
* Filed herewith.
** Furnished herewith.Previously filed or furnished.
# Management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CATASYS, INC. | |||
Date: | By: |
| |
| |||
| |||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
|
|
| ||
/s/ TERREN S. PEIZER | ||||
|
| |||
Terren S. Peizer |
| |||
Chief Executive Officer | ||||
|
|
| ||
|
| |||
|
|
| ||
|
| |||
| ||||
|
|
| ||
| ||||
|
|
| ||
| ||||
|
|
| ||
| ||||
|
|
| ||
| ||||
|
|
| ||
| ||||
|
|
| ||
|
CATASYS, INC. AND SUBSIDIARIES
Index to Consolidated Financial Statements and Financial Statement Schedules
Financial Statements
|
|
|
|
|
|
|
|
|
|
|
|
Financial Statement Schedules
All financial statement schedules are omitted because they are not applicable not required, or the information is shown in the Financial Statements or Notes thereto.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Catasys, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheet of Catasys, Inc. and Subsidiaries (the “Company") as of December 31, 2018, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2018, and the consolidated results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.
Change in Accounting Principle
As discussed in Note 5 to the financial statements, the Company has changed its method of accounting for revenue in the year ended December 31, 2018 due to the adoption of Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers”.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
/s/ EisnerAmper LLP
We have served as the Company’s auditor since 2018
EISNERAMPER LLP
Iselin, New Jersey
March 22, 2019
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheet of Catasys, Inc. and Subsidiaries (the Company) as of December 31, 2017, and the related statements of operations, stockholders’ equity (deficit), and cash flows for the year ended December 31, 2017, and the related notes to the consolidated financial statements (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017, and the results of its operations and its cash flows for the year ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.
Rose, Snyder & Jacobs LLP
We have served as the Company’s auditor since 2009.
Encino, California
March 7, 2018
CATASYS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except for number of shares) | December 31, | December 31, | ||||||
2018 | 2017 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash, cash equivalents and restricted cash | $ | 3,162 | $ | 4,779 | ||||
Receivables, net of allowance for doubtful accounts of $0 and $476, respectively | 1,382 | 511 | ||||||
Prepaids and other current assets | 942 | 366 | ||||||
Total current assets | 5,486 | 5,656 | ||||||
Long-term assets | ||||||||
Property and equipment, net of accumulated depreciation of $1,801 and $1,542, respectively | 263 | 612 | ||||||
Restricted cash, long term | 408 | - | ||||||
Deposits and other assets | 166 | 336 | ||||||
Total Assets | $ | 6,323 | $ | 6,604 | ||||
LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 497 | $ | 980 | ||||
Accrued compensation and benefits | 1,537 | 1,177 | ||||||
Deferred revenue | 4,195 | 2,914 | ||||||
Other accrued liabilities | 1,501 | 578 | ||||||
Total current liabilities | 7,730 | 5,649 | ||||||
Long-term liabilities | ||||||||
Long term debt, net of discount of $478 and $0, respectively | 7,472 | - | ||||||
Deferred rent and other long-term liabilities | - | 25 | ||||||
Capital leases | - | 2 | ||||||
Warrant liabilities | 86 | 30 | ||||||
Total Liabilities | 15,288 | 5,706 | ||||||
Commitments and contingencies (note 9) | ||||||||
Stockholders' (deficit)/equity | ||||||||
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding | - | - | ||||||
Common stock, $0.0001 par value; 500,000,000 shares authorized; 16,185,146 and 15,889,171 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively | 2 | 2 | ||||||
Additional paid in capital | 296,688 | 294,220 | ||||||
Accumulated deficit | (305,655 | ) | (293,324 | ) | ||||
Total Stockholders' (deficit)/equity | (8,965 | ) | 898 | |||||
Total Liabilities and Stockholders' (Deficit)/Equity | $ | 6,323 | $ | 6,604 | ||||
See accompanying notes to the consolidated financial statements
CATASYS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Year Ended | ||||||||
(In thousands, except per share amounts) | December 31, | |||||||
2018 | 2017 | |||||||
Revenues | ||||||||
Healthcare services revenues | $ | 15,177 | $ | 7,717 | ||||
Operating expenses | ||||||||
Cost of healthcare services | 11,119 | 6,391 | ||||||
General and administrative | 17,395 | 11,811 | ||||||
Depreciation and amortization | 288 | 246 | ||||||
Total operating expenses | 28,802 | 18,448 | ||||||
Loss from operations | (13,625 | ) | (10,731 | ) | ||||
Other income | 40 | 132 | ||||||
Interest expense | (570 | ) | (3,409 | ) | ||||
Loss on conversion of note | - | (1,356 | ) | |||||
Loss on issuance of common stock | - | (145 | ) | |||||
Change in fair value of warrant liability | (56 | ) | 1,778 | |||||
Change in fair value of derivative liability | - | 132 | ||||||
Loss before provision for income taxes | (14,211 | ) | (13,599 | ) | ||||
Provision for income taxes | 1 | 6 | ||||||
Net loss | $ | (14,212 | ) | $ | (13,605 | ) | ||
Basic and diluted net loss per share: | $ | (0.89 | ) | $ | (0.99 | ) | ||
Basic weighted number of shares outstanding | 15,955 | 13,751 | ||||||
See accompanying notes to the consolidated financial statements
|
|
Additional | ||||||||||||||||||||
(Amounts in thousands, except for number of shares) | Common Stock | Paid-In | Accumulated | |||||||||||||||||
Shares | Amount | Capital | Deficit | Total | ||||||||||||||||
Balance at December 31, 2016 | 9,214,743 | $ | 1 | $ | 254,390 | $ | (279,719 | ) | $ | (25,328 | ) | |||||||||
Conversion of debentures | 2,982,994 | - | 16,509 | - | 16,509 | |||||||||||||||
Common stock issued for outside services | 28,985 | - | 181 | - | 181 | |||||||||||||||
Warrants issued for services | - | - | 252 | - | 252 | |||||||||||||||
Deferred salary paid in common stock | 233,734 | - | 1,204 | - | 1,204 | |||||||||||||||
Public offering | 3,428,750 | 1 | 16,457 | - | 16,458 | |||||||||||||||
1:6 reverse stock split | (35 | ) | - | 63 | - | 63 | ||||||||||||||
Warrant liability write-off | - | - | 6,879 | - | 6,879 | |||||||||||||||
Transaction Costs | - | - | (2,180 | ) | - | (2,180 | ) | |||||||||||||
Share-based Compensation Expense | - | - | 465 | - | 465 | |||||||||||||||
Net loss | - | - | - | (13,605 | ) | (13,605 | ) | |||||||||||||
Balance at December 31, 2017 | 15,889,171 | $ | 2 | $ | 294,220 | $ | (293,324 | ) | $ | 898 | ||||||||||
Adoption of accounting standard | - | $ | - | $ | - | $ | 1,881 | $ | 1,881 | |||||||||||
Balance at January 1, 2018 | 15,889,171 | $ | 2 | $ | 294,220 | $ | (291,443 | ) | $ | 2,779 | ||||||||||
Common stock issued for outside services | 24,000 | - | 112 | - | 112 | |||||||||||||||
Warrants issued for services | - | - | 86 | - | 86 | |||||||||||||||
Warrants issued in connection with A/R facility | - | - | 64 | - | 64 | |||||||||||||||
Cashless warrant exercise | 241,975 | - | - | - | - | |||||||||||||||
Cash warrant exercise | 30,000 | - | 150 | - | 150 | |||||||||||||||
Share-based compensation expense | - | - | 2,056 | - | 2,056 | |||||||||||||||
Net loss | - | - | - | (14,212 | ) | (14,212 | ) | |||||||||||||
Balance at December 31, 2018 | 16,185,146 | $ | 2 | $ | 296,688 | $ | (305,655 | ) | $ | (8,965 | ) | |||||||||
See accompanying notes to the consolidated financial statements
| |||||
|
Year Ended | ||||||||
(In thousands) | December 31, | |||||||
2018 | 2017 | |||||||
Operating activities: | ||||||||
Net loss | $ | (14,212 | ) | $ | (13,605 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 288 | 246 | ||||||
Amortization of debt discount and issuance costs included in interest expense | 187 | 3,082 | ||||||
Loss on disposal of fixed asset | 70 | - | ||||||
Warrants issued for services | 86 | 252 | ||||||
Provision for doubtful accounts | - | 590 | ||||||
Deferred rent | (91 | ) | (81 | ) | ||||
Share-based compensation expense | 2,056 | 465 | ||||||
Common stock issued for services | 112 | 181 | ||||||
Loss on conversion of convertible note | - | 1,356 | ||||||
Loss on issuance of common stock, related party | - | 145 | ||||||
Fair value adjustment on warrant liability | 56 | (1,778 | ) | |||||
Fair value adjustment on derivative liability | - | (132 | ) | |||||
Changes in current assets and liabilities: | ||||||||
Receivables | (871 | ) | (49 | ) | ||||
Prepaids and other current assets | (311 | ) | 54 | |||||
Deferred revenue | 3,163 | 1,389 | ||||||
Accounts payable and other accrued liabilities | 893 | 517 | ||||||
Net cash used in operating activities | $ | (8,574 | ) | $ | (7,368 | ) | ||
Investing activities: | ||||||||
Purchases of property and equipment | $ | (9 | ) | $ | (448 | ) | ||
Deposits and other assets | 71 | 35 | ||||||
Net cash provided by (used in) investing activities | $ | 62 | $ | (413 | ) | |||
Financing activities: | ||||||||
Proceeds from the issuance of common stock and warrants | $ | - | $ | 16,458 | ||||
Proceeds from prom issuance of bridge loan, related party | - | 1,300 | ||||||
Payments on convertible debenture | - | (4,363 | ) | |||||
Proceeds from loan | 7,500 | - | ||||||
Transactions costs | - | (1,667 | ) | |||||
Capital lease obligations | (30 | ) | (19 | ) | ||||
Debt issuance costs | (317 | ) | - | |||||
Proceeds from warrant exercise | 150 | - | ||||||
Net cash provided by financing activities | $ | 7,303 | $ | 11,709 | ||||
Net (decrease) increase in cash, cash equivalents and restricted cash | $ | (1,209 | ) | $ | 3,928 | |||
Cash, cash equivalents and restricted cash at beginning of period | 4,779 | 851 | ||||||
Cash, cash equivalents and restricted cash at end of period | $ | 3,570 | $ | 4,779 | ||||
Supplemental disclosure of cash paid | ||||||||
Interest | $ | 363 | $ | 106 | ||||
Income taxes | $ | - | $ | 40 | ||||
Supplemental disclosure of non-cash activity | ||||||||
Common stock issued for services | $ | - | $ | 181 | ||||
Warrants issued for consulting services | $ | - | $ | 252 | ||||
Common stock issued for conversion of debt and accrued interest | $ | - | $ | 7,163 | ||||
Common stock issued upon settlement of deferred compensation to officer | $ | - | $ | 1,122 | ||||
Warrants issued in connection with A/R Facility | $ | 64 | $ | - | ||||
See accompanying notes to the consolidated financial statements
CATASYS, INC. AND SUBSIDIARIES
Notes toConsolidated Financial Statements
Note 1. Summary of Significant Accounting Policies
Description of Business
We harness proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and cost savings to health plans. We identify, engage and treat health plan members with unaddressed behavioral health conditions that worsen medical comorbidities. Our mission is to help improve the health and save the lives of as many people as possible.
We apply advanced data analytics and predictive modeling to identify members with untreated behavioral health conditions, whether diagnosed or not, and coexisting medical conditions that may be impacted through treatment in the OnTrak program. We then uniquely engage health plan members who do not typically seek behavioral healthcare by leveraging proprietary enrollment capabilities built on deep insights into the drivers of care avoidance. Our technology enabled OnTrak solution is an integrated suite of services that includes evidence-based psychosocial and medical interventions delivered either in-person or via telehealth, nurse-led care coaching and local community support. We believe that the program is currently improving member health and, at the same time, demonstrating reduced medical utilization, driving a reduction in total health plan costs for enrolled members.
We have contracted with leading national and regional health plans to make OnTrak available to eligible members in California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, Nebraska, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.
Basis of Consolidation, Presentation, and Liquidity
At December 31, 2018, cash and cash equivalents was $3.2 million and we had a working capital deficit of approximately $2.2 million. We could continue to incur negative cash flows and operating losses for the next twelve months. Our current cash burn rate is approximately $762,000 per month. We expect our current cash resources to cover expenses through at least the next twelve months, however, delays in cash collections, revenue, or unforeseen expenditures could impact this estimate.
Our ability to fund our ongoing operations is dependent on increasing the number of members that are eligible for our solutions by signing new contracts, identifying more eligible members in existing contracts, and generating fees from existing and new contracts and the success of management’s plan to increase revenue and continue to control expenses. We currently operate our OnTrak solutions in twenty-two states. We provide services to commercial (employer funded), managed Medicare Advantage, and managed Medicaid and duel eligible (Medicare and Medicaid) populations. We have generated fees from our launched programs and expect to increase enrollment and fees throughout 2019.
Management’s Plans
Historically, we have seen and continue to see net losses, net loss from operations, negative cash flow from operating activities, and historical working capital deficits as we continue through a period of rapid growth. The accompanying financial statements do not reflect any adjustments that might result if we were unable to continue as a going concern. We have alleviated substantial doubt by both entering into contracts for additional revenue-generating health plan customers and expanding our OnTrak program within existing health plan customers. To support this increased demand for services, we invested and will continue to invest in additional headcount needed to support the anticipated growth. Additional management plans include increasing the outreach pool as well as improving our current enrollment rate. We will continue to explore ways to increase margins on both existing and new members.
We have a growing customer base and believe we are able to fully scale our operations to service the contracts and future enrollment providing leverage in these investments that will generate positive cash flow by the end of 2019. We believe we will have enough capital to cover expenses through the foreseeable future and we will continue to monitor liquidity. If we add more health plans than budgeted, increase the size of the outreach pool by more than we anticipate, decide to invest in new products or seek out additional growth opportunities, we would consider financing these options with either a debt or equity financing.
All inter-company transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts in the financial statements and disclosed in the accompanying notes. Significant areas requiring the use of management estimates include expense accruals, accounts receivable allowances, accrued claims payable, the useful life of depreciable and amortizable assets, revenue recognition, the valuation of warrant liabilities, and shared-based compensation. Actual results could differ from those estimates.
Revenue Recognition
Revenue from contracts with customers is recognized when, or as, we satisfy our performance obligations by transferring the promised goods or services to the customers. A good or service is transferred to a customer when, or as, the customer obtains control of that good or service. A performance obligation may be satisfied over time or at a point in time. Revenue from a performance obligation satisfied over time is recognized by measuring our progress in satisfying the performance obligation in a manner that depicts the transfer of the goods or services to the customer. Revenue from a performance obligation satisfied at a point in time is recognized at the point in time that we determine the customer obtains control over the promised good or service. The amount of revenue recognized reflects the consideration we expect to be entitled to in exchange for those promised goods or services (i.e., the “transaction price”). In determining the transaction price, we consider multiple factors, including the effects of variable consideration. Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. In determining when to include variable consideration in the transaction price, we consider the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties.
The following table disaggregates our revenue by contract:
For the year ended | For the year ended | |||||||||||||||
(in thousands) | Revenue | Percentage | Revenue | Percentage | ||||||||||||
Commercial | $ | 9,495 | 63% | $ | 2,661 | 34% | ||||||||||
Government | 5,682 | 37% | 5,056 | 66% | ||||||||||||
| $ | 15,177 | 100% | $ | 7,717 | 100% | |||||||||||
Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis, an upfront case rate, or fee for service based on enrolled members. The Company’s performance obligation is satisfied over time as the OnTrak service is provided continuously throughout the service period. The Company recognizes revenue evenly over the service period using a time-based measure because the Company is providing a continuous service to the customer. Contracts with minimum performance guarantees or price concessions include variable consideration and are subject to the revenue constraint. The Company uses an expected value method to estimate variable consideration for minimum performance guarantees and price concessions. The Company has constrained revenue for expected price concessions during the year ended December 31, 2018.
Cost of Services
Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists and other staff directly involved in member care, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Salaries and fees charged by our third party administrators for processing claims are expensed when incurred and healthcare provider claims payments are recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the OnTrakTM database within the contracted timeframe, with all required billing elements correctly completed by the service provider.
Cash and Cash Equivalents
We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of December 31, 2018, we had $2.5 million in cash and cash equivalents exceeding federally insured limits.
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years.
Share-Based Compensation
Stock Options – Employees and Directors
We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations. We recognize forfeitures when they occur.
There were 1,985,539 and 1,674,864 options granted for the years ended December 31, 2018 and 2017, respectively.
The stock compensation expense was calculated using the Black-Scholes model based on upon the following assumptions:
December 31, 2018 | December 31, 2017 | |||||||||
Expected volatility | 100.34% | - | 102.90 | % | 102.90 | % | ||||
Risk-free interest rate | 2.56 | - | 2.85 | % | 2.23 | - | 2.46 | % | ||
Weighted average expected lives in years | 2.4 | - | 6.08 | 10 | ||||||
Expected dividend | 0 | % | 0 | % | ||||||
The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the year ended December 31, 2018, reflects the application of the simplified method prescribed in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 107 (as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.
As of December 31, 2018, there was $6.2 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2017 Amended Plan. That cost is expected to be recognized over a weighted-average period of approximately 3.12 years.
Stock Options and Warrants – Non-employees
We account for the issuance of stock options and warrants for services from non-employees by estimating the fair value of stock options and warrants issued using the Black-Scholes pricing model. This model’s calculations incorporate the exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, expected life of the option or warrant, expected volatility of our stock and expected dividends.
For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.
There were no options issued to non-employees for the year ended December 31, 2018 and 2017, respectively.
There was no share based compensation expense relating to stock options recognized for the non-employees for the year ended December 31, 2018 and 2017, respectively.
There were 24,000 warrants issued in exchange for services during the year ended December 31, 2018 valued at $86,000, and 90,000 warrants issued in exchange for services during 2017 valued at $252,000. Generally, the costs associated with warrants issued for services are amortized to the related expense on a straight-line basis over the related service periods.
There were 9,720 warrants issued in connection with the June 2018 A/R Facility financing (see Footnote 12).
In September 2018, there was a cashless exercise of 250,002 warrants in exchange for the issuance of 174,015 shares of our common stock, par value $0.0001 (“Common Stock”).
In November 2018, there was a cashless exercise of 156,250 warrants in exchange for the issuance of 67,960 shares of our Common Stock.
In December 2018, there was exercise of 30,000 warrants at an exercise price of $5.00 per share. We received $150,000 in proceeds and issued 30,000 shares of our Common Stock.
There were 1,608,996 and 2,011,528 warrants outstanding as of December 31, 2018 and 2017, respectively.
From time to time, we have retained terminated employees as part-time consultants upon their departure from the company. Because the employees continue to provide services to us, their options continue to vest in accordance with the original terms. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards under FASB’s accounting rules for share-based expense but are instead accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. There were no employees moved to consulting status for the years ended December 31, 2018 and 2017, respectively.
Income Taxes
We account for income taxes using the liability method in accordance with Accounting Standards Committee (“ASC”) 740 “Income Taxes”. To date, no current income tax liability has been recorded due to our accumulated net losses. Deferred tax assets and liabilities are recognized for temporary differences between the financial statement carrying amounts of assets and liabilities and the amounts that are reported in the tax returns. Deferred tax assets and liabilities are recorded on a net basis; however, our net deferred tax assets have been fully reserved by a valuation allowance due to the uncertainty of our ability to realize future taxable income and to recover our net deferred tax assets.
Basic and Diluted Income (Loss) per Share
Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock and dilutive common equivalent shares outstanding during the period.
Common equivalent shares, consisting of approximately 5,370,274 and 3,896,911 of shares as of December 31, 2018 and 2017, respectively, issuable upon the exercise of stock options and warrants, have been excluded from the diluted earnings per share calculation because their effect is anti-dilutive.
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:
|
| |
|
| |
|
| |
|
|
The following tables summarize fair value measurements by level at December 31, 2018 and 2017, respectively, for assets and liabilities measured at fair value on a recurring basis:
Balance at December 31, 2018 | ||||||||||||||||
(Amounts in thousands) | Level I | Level II | Level III | Total | ||||||||||||
Certificates of deposits (1) | 479 | - | - | 479 | ||||||||||||
Total assets | 479 | - | - | 479 | ||||||||||||
Warrant liabilities | - | - | 86 | 86 | ||||||||||||
Total liabilities | - | - | 86 | 86 | ||||||||||||
|
Balance at December 31, 2017 | ||||||||||||||||
(Amounts in thousands) | Level I | Level II | Level III | Total | ||||||||||||
Certificates of deposit | 71 | - | - | 71 | ||||||||||||
Total assets | 71 | - | - | 71 | ||||||||||||
Warrant liabilities | - | - | 30 | 30 | ||||||||||||
Total liabilities | - | - | 30 | 30 | ||||||||||||
Financial instruments classified as Level III in the fair value hierarchy as of December 31, 2018, represent our liabilities measured at market value on a recurring basis which include warrant liabilities. In accordance with current accounting rules, the warrant liabilities are being marked-to-market each quarter-end until they are completely settled or expire. The warrants are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See Warrant Liabilities below.
The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the years ended December 31, 2018 and 2017:
Level III | ||||
Warrant | ||||
(Amounts in thousands) | Liabilities | |||
Balance as of December 31, 2016 | $ | 5,307 | ||
Issuance (exercise) of warrants, net | 2,674 | |||
Change in fair value | (1,778 | ) | ||
Write off of warrants | (6,173 | ) | ||
Balance as of December 31, 2017 | $ | 30 | ||
Issuance of warrants | - | |||
Change in fair value | 56 | |||
Balance as of December 31, 2018 | $ | 86 | ||
Capital Leases
Assets held under capital leases include computer equipment, and are recorded at the lower of the net present value of the minimum lease payments or the fair value of the leased asset at the inception of the lease. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets. All lease agreements meet at least one of the four requirements of a capital lease in accordance with ASC 840 of the codification.
Variable Interest Entities
Generally, an entity is defined as a Variable Interest Entity (“VIE”) under current accounting rules if it either lacks sufficient equity to finance its activities without additional subordinated financial support, or it is structured such that the holders of the voting rights do not substantively participate in the gains and losses of the entity. When determining whether an entity that meets the definition of a business, qualifies for a scope exception from applying VIE guidance, we consider whether: (i) we participated significantly in the design of the entity, (ii) we provided more than half of the total financial support to the entity, and (iii) substantially all of the activities of the VIE are conducted on our behalf. A VIE is consolidated by its primary beneficiary, the party that has the power to direct the activities that most significantly affect the economics of the VIE and has the right to receive benefits or the obligation to absorb losses of the entity that could be potentially significant to the VIE. The primary beneficiary assessment must be re-evaluated on an ongoing basis.
As discussed under the heading Management Services Agreement (“MSA”) below, we have an MSA with a Texas nonprofit health organization (“TIH”) and a California Professional Corporation (“CIH”). Under the MSA’s, the equity owners of TIH and CIH have only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or benefits. We participate significantly in the design of this MSA’s. We also agree to provide working capital loans to allow for TIH and CIH to fund their day to day obligations. Substantially all of the activities of TIH and CIH include our decision making, approval or are conducted for our benefit, as evidenced by the facts that (i) the operations of TIH and CIH are conducted primarily using our licensed network of providers and (ii) under the MSA, we agree to provide and perform all non-medical management and administrative services for the entities. Payment of our management fee is subordinate to payments of the obligations of TIH and CIH, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated medical group or other third party. Creditors of TIH and CIH do not have recourse to our general credit.
Based on the design of the entity and the lack of sufficient equity to finance its activities without additional working capital loans we have determined that TIH and CIH are VIE’s. We are the primary beneficiary required to consolidate the entity as we have power and potentially significant interests in the entity.
Management Services Agreement
In April 2018, we executed an MSA with TIH and in July 2018, we executed an MSA with CIH. Under the MSA’s, we license to TIH and CIH the right to use our proprietary treatment programs and related trademarks and provide all required day-to-day business management services, including, but not limited to:
|
| |
|
| |
|
| |
|
| |
|
|
All clinical matters relating to the operation of TIH and CIH and the performance of clinical services through the network of providers shall be the sole and exclusive responsibility of the TIH and CIH Board free of any control or direction by Catasys.
TIH pays us a monthly fee equal to the aggregate amount of (a) our costs of providing management services (including reasonable overhead allocable to the delivery of our services and including salaries, rent, equipment, and tenant improvements incurred for the benefit of the medical group, provided that any capitalized costs will be amortized over a five-year period), (b) 10%-15% of the foregoing costs, and (c) any performance bonus amount, as determined by TIH at its sole discretion. The payment of our fee is subordinate to payment of the entities’ obligations.
CIH pays us a monthly fee equal to the aggregate amount of (a) our costs of providing management services (including reasonable overhead allocable to the delivery of our services and including salaries, rent, equipment, and tenant improvements incurred for the benefit of the entity, provided that any capitalized costs will be amortized over a five-year period), and (b) any performance bonus, as determined by CIH at its sole discretion.
Under the MSA’s, the equity owner of the affiliated treatment center has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We also agree to provide working capital loans to allow for TIH and CIH to pay for their obligations. Substantially all of the activities of TIH and CIH either involves us or are conducted for our benefit, as evidenced by the facts that (i) the operations of TIH and CIH is conducted primarily using our licensed protocols and (ii) under the MSA’s, we agree to provide and perform all non-medical management and administrative services for the TIH and CIH. Payment of our management fee is subordinate to payments of the obligations of TIH and CIH, and repayment of the working capital loans is not guaranteed by the equity owner of TIH and CIH or other third party. Creditors of TIH and CIH do not have recourse to our general credit. Based on these facts, we have determined that TIH and CIH are VIE’s and that we are the primary beneficiary as defined in current accounting rules. Accordingly, we are required to consolidate the assets, liabilities, revenues and expenses of the managed treatment center.
The amounts and classification of assets and liabilities of the VIE included in our consolidated balance sheets at December 31, 2018 are as follows:
(in thousands) | December 31, 2018 | |||
Cash and cash equivalents | $ | 45 | ||
Accounts Receivable | 94 | |||
Prepaid and Other Current Assets | 29 | |||
Total Assets | $ | 168 | ||
Accounts payable | $ | 7 | ||
Accrued liabilities | 14 | |||
Total Liabilities | $ | 21 | ||
Warrant Liabilities
The warrant liabilities were calculated using the Black-Scholes model based on upon the following assumptions:
December 31, 2018 | December 31, 2017 | |||||||
Expected volatility | 102.90 | % | 102.90 | % | ||||
Risk-free interest rate | 2.63 | % | 1.89 | % | ||||
Weighted average expected lives in years | 1.29 | 2.29 | ||||||
Expected dividend | 0 | % | 0 | % | ||||
For the years ended December 31, 2018 and 2017, we recognized a loss of $56,000 and a gain of $1.8 million, respectively, related to the revaluation of our warrant liabilities.
Concentration of Credit Risk
Financial instruments, which potentially subject us to a concentration of risk, include cash, restricted cash and accounts receivable. All of our customers are based in the United States at this time and we are not subject to exchange risk for accounts receivable.
The Company maintains its cash in domestic financial institutions subject to insurance coverage issued by the Federal Deposit Insurance Corporation (FDIC). Under FDIC rules, the company is entitled to aggregate coverage as defined by the Federal regulation per account type per separate legal entity per financial institution. The Company has incurred no losses as a result of any credit risk exposures.
For the year ended December 31, 2018, four customers accounted for approximately 76% of revenues (25%, 25%, 13% and 13%) and four customers accounted for approximately 88% of accounts receivable (31%, 27%, 16% and 14%).
For the year ended December 31, 2017, four customers accounted for approximately 90% of revenues (36%, 23%, 21%, 10%) and four customers accounted for approximately 96% (35%, 29%, 17%, 15%) of accounts receivable.
Recently Issued or Newly Adopted Accounting Pronouncements
In August 2018, the FASB issued Accounting Standard Update (“ASU”) No. 2018-13, Fair Value Measurement (Topic 820), which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, including, among other changes, the consideration of costs and benefits when evaluating disclosure requirements. For public companies, the amendments are effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted. We are currently assessing the impact that adopting this new accounting guidance will have on our financial statements and footnote disclosures.
In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. For public companies, the amendments are effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but no earlier than a company's adoption date of ASC 606. We do not believe that the adoption of ASU 2018-07 will have a material impact on our consolidated financial statements.
In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). The amendments in this update are intended to simplify the accounting for certain equity linkedfinancial instruments and embedded features with down round features that result in the strike price being reduced on the basis of the pricing of futureequity offerings. Under the new guidance, a down round feature will no longer need to be considered when determining whether certain financial instrumentsor embedded features should be classified as liabilities or equity instruments. That is, a down round feature will no longer preclude equity classification whenassessing whether an instrument or embedded feature is indexed to an entity's own stock. In addition, the amendments clarify existing disclosurerequirements for equity-classified instruments. These amendments are effective for fiscal years, and interim periods within those years, beginning afterDecember 15, 2018, with early adoption permitted. We do not believe that the adoption of ASU 2017-11 will have a material impact on our consolidated financial statements.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”), which clarifies the presentation of restricted cash in the statements of cash flows. Under ASU 2016-18, restricted cash is included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statements of cash flows. The Company adopted ASU 2016-18 as of January 1, 2018. The following is a summary of cash, cash equivalents and restricted cash total as presented in the statements of cash flows for the years December 31, 2018, and 2017:
(in thousands) | 2018 | 2017 | ||||||
Cash and cash equivalents | $ | 3,091 | $ | 4,779 | ||||
Restricted cash (current and long-term) | 479 | - | ||||||
Total cash, cash equivalents and restricted cash | $ | 3,570 | $ | 4,779 | ||||
In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606) (“ASU 2016-10”), which amends certain aspects of the Board’s new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09, which is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. We have selected the modified retrospective approach as our transition method under ASU 2016-10 and the financial impact to the financial statements was to decrease retained earnings and deferred revenue by $1.9 million effective January 1, 2018 (Please see footnote 5).
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (“ASU 2016-13”). The amendment revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to, available for sale debt securities and accounts receivable. The Company is required to adopt this standard starting in the first quarter of fiscal year 2021. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements and related disclosures.
In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). Under this standard, which applies to both lessors and lessees, lessees will be required to recognize all leases (except for short-term leases) as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease measured on a discounted basis, and as a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018 and is to be applied at the beginning of the earliest period presented using a modified retrospective approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available. Based on the Company’s leases in place on January 1, 2019 and considering the practical expedients, the Company expects that adoption of the new standard will not have a material effect on its consolidated statements of operations, will result in a gross-up on our consolidated balance sheets of less than $200,000 and will have no effect on our consolidated statements of cash flows.
Note 2. Accounts Receivable
Accounts receivables consisted of the following as of December 31, 2018 and 2017:
December 31, | ||||||||
(in thousands) | 2018 | 2017 | ||||||
Healthcare fees | $ | 1,382 | $ | 985 | ||||
Other | - | 2 | ||||||
Total receivables | $ | 1,382 | $ | 987 | ||||
Less allowance for doubtful accounts | - | (476 | ) | |||||
Total receivables, net | $ | 1,382 | $ | 511 | ||||
We use the specific identification method for recording the provision for doubtful accounts, there was no allowance for doubtful accounts as of December 31, 2018 and $476,000 as of December 31, 2017.
Note 3. Property and Equipment
Property and equipment consisted of the following as of December 31, 2018 and 2017:
(in thousands) | 2018 | 2017 | ||||||
Furniture and equipment | $ | 1,746 | $ | 1,836 | ||||
Leasehold improvements | 318 | 318 | ||||||
Total property and equipment | 2,064 | 2,154 | ||||||
Less accumulated depreciation and amortization | (1,801 | ) | (1,542 | ) | ||||
Total property and equipment, net | $ | 263 | $ | 612 | ||||
Depreciation expense was $288,000 and $246,000 for the years ended December 31, 2018 and 2017, respectively.
Note 4. Capital Lease Obligations
We lease certain computer equipment under agreements entered into during 2016 that are classified as capital leases. The computer equipment under capital leases is included in furniture and equipment on our consolidated balance sheets and was $68,000 and $86,000 as of December 31, 2018 and 2017, respectively. Accumulated depreciation of the leased equipment at December 31, 2018 and 2017 was approximately $63,000 and $59,000, respectively.
The future minimum lease payments required under the capital leases and the present values of the net minimum lease payments as of December 31, 2018, is as follows and is included under the caption other current liabilities on the consolidated balance sheet :
(in thousands) | Amount | |||
Year ending December 31, | ||||
2019 | $ | 2 | ||
Total minimum lease payments | 2 | |||
Less amounts representing interest | - | |||
Capital lease obligations, net of interest | 2 | |||
Less current maturities of capital lease obligations | (2 | ) | ||
Long-term capital lease obligations | $ | - | ||
Note 5. ASC 606
Revenue Recognition
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606),(“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC 605 - Revenue Recognition (“ASC 605”) and most industry-specific guidance throughout ASC 605. The FASB has issued numerous updates that provide clarification on a number of specific issues as well as requiring additional disclosures. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.
We adopted ASC 606 effective January 1, 2018 using the modified retrospective method. We recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. The cumulative effect of the changes made to our consolidated January 1, 2018 balance sheet for the adoption of ASU 2014-09were as follows (in thousands):
Balance at December 31, 2017 | Adjustments Due to Adoption of ASC606 | Balance at January 1, 2018 | ||||||||||
Balance Sheet | ||||||||||||
Liabilities | ||||||||||||
Deferred revenue | (2,914 | ) | 1,881 | (1,033 | ) | |||||||
Equity | ||||||||||||
Retained earnings | (293,324 | ) | 1,881 | (291,443 | ) | |||||||
In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated income statement and balance sheet for the year ended December 31, 2018 was as follows (in thousands):
Year Ended December 31, 2018 | ||||||||||||
As | Balances Without Adoption of | Effect of Change | ||||||||||
Income Statement | ||||||||||||
Revenues | ||||||||||||
Healthcare services revenues | $ | 15,177 | $ | 9,349 | $ | 5,828 | ||||||
Net loss | (14,212 | ) | (20,040 | ) | 5,828 | |||||||
Note 6. Income Taxes
As of December 31, 2018, the Company had net federal operating loss carry forwards and state operating loss carry forwards of approximately $260 million and $186 million, respectively. The net federal operating loss carry forwards begin to expire in 2023, and net state operating loss carry forwards begin to expire in 2018.
Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains a valuation allowance of $64.1 million and $62.4 million against all of its deferred tax assets as of December 31, 2018 and 2017, respectively. For the years ended December 31, 2018 and 2017, the total change in valuation allowance was $1.7 million and $29.0 million, respectively. Realization of the deferred tax assets will be primarily dependent upon the Company's ability to generate sufficient taxable income.
The primary components of temporary differences which give rise to our net deferred tax assets are as follows:
2018 | 2017 | |||||||
(in thousands) | ||||||||
Federal, state and foreign net operating losses | $ | 62,800 | $ | 53,911 | ||||
Stock based compensation | 873 | 4,937 | ||||||
Accrued liabilities | 218 | 157 | ||||||
Fixed Assets | 72 | - | ||||||
Other temporary differences | 315 | 3,426 | ||||||
Prepaid expenses | (176 | ) | - | |||||
Valuation allowance | (64,102 | ) | (62,431 | ) | ||||
| $ | - | $ | - | |||||
The Company has provided a valuation allowance in full on its net deferred tax assets in accordance with ASC 740 Income Taxes. Because of the Company's continued losses, management assessed the realizability of its net deferred tax assets as being less than the more-likely-than-not criteria set forth by ASC 740. Furthermore, certain portions of the Company's net operating loss carryforwards were acquired, and therefore subject to further limitation set forth under the federal tax code, which could further limit the Company's ability to realize its deferred tax assets.
A reconciliation between the statutory federal income tax rate and the effective income tax rate for the years ended December 31, is as follows
2018 | 2017 | |||||||
Federal statutory rate | 21.0 | % | -34.0 | % | ||||
State taxes, net of federal benefit | 0.0 | % | -5.5 | % | ||||
Non-deductible share-based compensation | -29.3 | % | 0.0 | % | ||||
Deferred Revenue | -2.8 | % | 0.0 | % | ||||
Change in Foreign NOLS due to liquidation | -8.3 | % | 0.0 | % | ||||
ISO / ESPP | 0.0 | % | 0.3 | % | ||||
Other | 3.3 | % | 249.6 | % | ||||
Change in federal and foreign allowance | 16.1 | % | -210.4 | % | ||||
Tax provision | 0.0 | % | 0.0 | % | ||||
Current accounting rules require that companies recognize in the consolidated financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. We file income tax returns in the U.S. federal jurisdiction and various states. Tax years that remain subject to examinations by tax authorities are 2015 through 2017. There are currently no income tax audits in any jurisdictions for open tax years and, as of December 31, 2018, there have been no material changes to our tax positions.
The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. There were no interest and penalties for the years ended December 31, 2018 and 2017, respectively. The Company files income tax returns with the Internal Revenue Service (“IRS”) and various states with sufficient nexus. For jurisdictions in which tax filings are prepared, the Company is no longer subject to income tax examinations by state tax authorities for tax years prior to 2014, and by the IRS for tax years through 2015. The Company’s net operating loss carryforwards are subject to IRS examination until they are fully utilized and such tax years are closed.
Under Section 382 of the Internal Revenue Code of 1986, as amended, or the IRC, substantial changes in our ownership may limit the amount of net operating loss and research and development income tax credit carryforwards that could be utilized annually in the future to offset taxable income. Specifically, this limitation may arise in the event of a cumulative change in ownership of the company of more than 50% within a three-year testing period. Any such annual limitation may significantly reduce the utilization of the net operating loss carryforwards before they expire.
Since the Company's formation, the Company has raised capital through the issuance of capital stock on several occasions which, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition. The Company intends to complete a study in the future to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation.
Note 7. Common Stock
In September 2018, there was a cashless exercise of 250,002 warrants in exchange for the issuance of 174,015 shares of our Common Stock.
In November 2018, there was a cashless exercise of 156,250 warrants in exchange for the issuance of 67,960 shares of our Common Stock.
In December 2018, there was exercise of 30,000 warrants at an exercise price of $5.00 per share. We received $150,000 of proceeds and issued 30,000 shares of our Common Stock.
In April 2017, we entered into an underwriting agreement with Joseph Gunnar & Co., LLC (“Joseph Gunnar”), as underwriter in connection with a public offering of the Company’s securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate 3,125,000 shares of common stock at a public offering price of $4.80 per share, and the purchase price to the underwriter after discounts and commission was $4.464 per share. The closing of the offering occurred on April 28, 2017. We received $15.0 million in gross proceeds in connection with the offering.
Pursuant to the underwriting agreement with Joseph Gunnar, we granted the underwriters a 45 day over-allotment option to purchase up to 468,750 additional shares of common stock at the public offering price less the applicable underwriter discount. In May, the underwriter acquired an additional 303,750 shares pursuant to such over-allotment option. We received $1.5 million in gross proceeds in connection with the over-allotment option.
In connection with the public offering, our common stock began trading on the NASDAQ Capital Market (“NASDAQ”) under the symbol “CATS” beginning on April 26, 2017.
In April 2017, several investors, including Acuitas and Shamus exercised their option to convert their convertible debentures and received 2,982,994 shares of common stock. There was a loss on the conversion of the convertible debentures of $1.4 million for the twelve months ended December 31, 2017.
In April 2017, Terren S. Peizer agreed to settle his deferred salary balance of $1.1 million for 233,734 shares of common stock. As a result, we recognized a loss on settlement of liability totaling $83,807 which is recorded to loss on issuance of common stock.
In April 2017, we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a 1-for-6 reverse stock split of our common stock, pursuant to which each six shares of issued and outstanding common stock converted into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. No fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares.
All stock options and warrants to purchase common stock outstanding and our common stock reserved for issuance under our equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by six and, as applicable, multiplying the exercise price by six as a result of the reverse stock split.
During 2018 and 2017, we issued 24,000 and 28,985 shares of common stock, respectively, for consulting services valued at $112,000 and $181,000, respectively. Generally, the costs associated with shares issued for services are being amortized to the related expense on a straight-line basis over the related service periods.
Note 8. Share-based Compensation
Our 2017 Stock Incentive Plan (the “2017 Plan”), provides for the issuance of up to 2,333,334 shares of our common stock and an additional 243,853 shares of our common stock that are represented by awards granted under our 2010 Stock Incentive Plan (the “2010 Plan”). In August 2018, at our Annual Stockholders Meeting, Stockholders approved an amendment to the Company's 2017 Plan, among other things, to provide for an additional 1,400,000 shares to be issued in connection with awards granted thereunder (the “2017 Amended Plan”). Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the 2017 Amended Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants; however, option rights expire no later than ten years from the date of grant and employee and Board of Director awards generally vest over three to five years on a straight-line basis. As of December 31, 2018, we had 3,761,278 vested and unvested stock options outstanding and 215,909 shares reserved for future awards.
Share-based compensation expense was approximately $2.1 million and $465,000 for the years ended December 31, 2018 and 2017, respectively.
Stock Options – Employees and Directors
There were 1,985,539 and 1,674,864 stock options granted during 2018 and 2017, respectively. The estimated weighted average fair value of the options granted during 2018 was approximately 7.70 per share.
Stock option activity for employee and director grants is summarized as follows:
Weighted Avg. | Aggregate | |||||||||||
Shares (#) | Exercise Price | Intrinsic Value | ||||||||||
Balance, December 31, 2016 | 244,046 | $ | 38.94 | $ | - | |||||||
2017 | ||||||||||||
Granted | 1,674,864 | 7.50 | - | |||||||||
Cancelled/Expired | (33,527 | ) | 14.54 | - | ||||||||
Balance, December 31, 2017 | 1,885,383 | $ | 11.46 | $ | - | |||||||
Exercisable at December 31, 2017 | 306,612 | $ | 31.49 | $ | - | |||||||
2018 | ||||||||||||
Granted | 1,985,539 | 7.70 | - | |||||||||
Cancelled/Expired | (109,644 | ) | 14.29 | - | ||||||||
Balance, December 31, 2018 | 3,761,278 | $ | 9.44 | $ | - | |||||||
Exercisable at December 31, 2018 | 721,766 | $ | 17.14 | $ | - | |||||||
The weighted average remaining contractual life and weighted average exercise price of options outstanding as of December 31, 2018 were as follows:
Options Outstanding | Options Exercisable | |||||||||||||||||||||
Range of Exercise Prices | Shares | Weighted Average Remaining Life (yrs) | Weighted Average Price | Shares | Weighted Average Price | |||||||||||||||||
$0.00 | to | $10.00 | 3,412,793 | 8.60 | $ | 7.52 | 465,315 | $ | 8.00 | |||||||||||||
$10.01 | to | $100.00 | 347,790 | 5.59 | 26.12 | 255,756 | 32.00 | |||||||||||||||
$100.01 | to | $1,200.00 | 695 | 0.81 | 1,108.25 | 695 | 1,108.25 | |||||||||||||||
| 3,761,278 | 8.32 | $ | 9.44 | 721,766 | $ | 17.14 | ||||||||||||||||
Share-based compensation expense relating to stock options granted to employees and directors was $2.1 million and $465,000 for the years ended December 31, 2018 and 2017, respectively.
As of December 31, 2018, there was $6.2 million of unrecognized compensation costs related to non-vested share-based compensation arrangements granted to employees and directors under the Plan. These costs are expected to be recognized over a weighted-average period of 3.12 years.
Stock Options and Warrants – Non-employees
In addition to stock options granted under the Plan, we have also granted warrants to purchase our common stock to certain non-employees that have been approved by our Board of Directors.
Warrants granted to non-employees outstanding as of December 31, 2018 and 2017, respectively, are summarized as follows:
December 31, 2018 | ||||||||
Description | Shares (#) | Weighted Average Exercise Price | ||||||
Warrants issued in connection with equity offering | - | $ | - | |||||
Warrants issued in connection with debt agreements | 9,720 | 7.72 | ||||||
Warrants issued for services | 24,000 | 4.68 | ||||||
| 33,720 | $ | 5.56 | ||||||
December 31, 2017 | ||||||||
Description | Shares | Weighted Average Exercise Price | ||||||
Warrants issued in connection with equity offering | 156,250 | $ | 6.00 | |||||
Warrants issued in connection with debt agreements | 451,918 | 4.51 | ||||||
Warrants issued for services | 90,000 | 5.00 | ||||||
| 698,168 | $ | 4.91 | ||||||
The following is a summary of warrant activity for the year ended December 31, 2018 and 2017:
Weighted avg. | ||||||||
Shares | exercise price | |||||||
Outstanding, December 31, 2016 | 1,313,360 | $ | 4.82 | |||||
2017 | ||||||||
Issued | 698,168 | 4.90 | ||||||
Exercised | - | - | ||||||
Outstanding, December 31, 2017 | 2,011,528 | $ | 28.40 | |||||
2018 | ||||||||
Issued | 33,720 | 5.56 | ||||||
Exercised | (436,252 | ) | (4.70 | ) | ||||
Outstanding, December 31, 2018 | 1,608,996 | $ | 4.71 | |||||
Note 9. Commitments and Contingencies
Operating Lease Commitments
We incurred rent expense of approximately $296,000 for the years ended December 31, 2018 and 2017, respectively.
Our principal executive and administrative offices are located in Los Angeles, California and consist of leased office space totaling approximately 9,120 square feet. The initial term of the lease expires in April 2019. Our base rent is currently approximately $33,000 per month, subject to annual adjustments. In September 2018, we entered into a lease for new our corporate offices in Santa Monica, California for 7,869 rentable square feet. The lease is for 48 months beginning in April 2019, base rent payment is approximately $48,000 per month, subject to annual adjustments.
Rent expense is calculated using the straight-line method based on the total minimum lease payments over the initial term of the lease. Landlord tenant improvement allowances and rent expense exceeding actual rent payments are accounted for as deferred rent liability in the balance sheet and amortized on a straight-line basis over the initial term of the respective leases.
Future minimum payments, by year and in the aggregate, under non-cancelable operating leases with initial or remaining terms of one year or more, consist of the following at December 31, 2018:
(in thousands) | ||||
Year | Amount | |||
2019 | $ | 406 | ||
2020 | 585 | |||
2021 | 605 | |||
2022 | 626 | |||
2023 | 648 | |||
| $ | 2,870 | |||
Future minimum payments primarily relates to our new office lease in Santa Monica, California.
Legal Proceedings
From time to time, we may be involved in certain legal actions and claims arising in the ordinary course of business. The Company was not a party to any specific legal actions or claims as of December 31, 2018.
Note 10. Related Party Disclosure
In January 2017, we entered into the Subscription Agreement with Acuitas pursuant to which we received aggregate gross proceeds of $1.3 million and warrants to purchase 254,904 shares of common stock. In April 2017, we used the net proceeds from the public offering to repay the Loan Amount including interest of $1.3 million.
In January 2017, in connection with the Subscription Agreement described above, the number of Acuitas warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 137,883 shares of our common stock.
In March 2017, we entered into an amendment with Acuitas of certain outstanding warrants issued in July 2015 to eliminate certain anti-dilution provisions in such warrants. Such amendment was contingent upon and did not take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Acuitas received additional warrants to purchase 31,167 shares of our common stock in April 2017.
In April 2017, Acuitas purchased 181,154 shares of common stock for $869,539 in proceeds in connection with the public offering.
In April 2017, Acuitas converted its July 2015 convertible debenture totaling $4.3 million of principal and interest into 2,385,111 shares of common stock.
In April 2017, we used net proceeds from the public offering to repay Acuitas the December 2016 8% convertible debenture with accrued interest of $2.9 million.
In April 2017, Terren S. Peizer agreed to settle his deferred salary balance of $1.1 million for 233,734 shares of common stock, resulting in a loss on settlement of liability totaling $83,807 recorded to loss on issuance of common stock.
In addition, we have accounts payable outstanding with Mr. Peizer for travel and expenses of approximately $378,000 and $254,000 as of December 31, 2018 and 2017, respectively.
Note 11. Short-term Debt
In March 2017, we entered into amendments with the holders of certain outstanding warrants issued on April 17, 2015 and July 30, 2015 to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of $5.3 million on our balance sheet as of December 31, 2016. Such amendments were contingent upon and did not take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of 11,049 shares of common stock, did not agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor, who received additional warrants to purchase 31,167 and 13,258 shares of our common stock. In addition, several warrant agreements that had anti-dilution protection had a provision in the agreement that upon an up-listing to NASDAQ, the anti-dilution protection would be removed. The up-listing to NASDAQ occurred on April 26, 2017. The elimination of the anti-dilution provision resulted in the write-off of $6.2 million of the warrant liability as of December 31, 2017.
In January 2017, we entered into a Subscription Agreement (the "Subscription Agreement") with Acuitas, pursuant to which we received aggregate gross proceeds of $1,300,000 (the "Loan Amount") in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 (the "January 2017 Convertible Debenture") and (ii) 254,904 five-year warrants to purchase shares of the Company's common stock which is equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the "January 2017 Warrants"). In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company's common stock. Acuitas agreed to extend the maturity date of the January 2017 Convertible Debenture to April 30, 2017 or until we completed a public offering, whichever came first. In April 2017, we used the net proceeds from the public offering to repay the Loan Amount including interest of $1.3 million.
Note 12. Long-Term Debt
In June 2018 we entered into a venture loan and security agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Lender”), which provides for up to $7.5 million in loans to us, including initial loans in the amount of $5.0 million funded upon signing of the Loan Agreement. An additional $2.5 million loan was subject to us achieving billings of not less than $5.0 million during any three consecutive month period on or prior to November 30, 2018. In August 2018, we incurred the additional $2.5 million loan as a result of our achievement of the trailing three month billings exceeding $5.0 million on or prior to November 30, 2018.
Repayment of the loans is on an interest-only basis through September 1, 2019, followed by monthly payments of principal and accrued interest for the balance of the term, subject to extension in the event that our billings exceed $20.0 million during the six months period ended June 30, 2019. The loans bear interest at a floating coupon rate of 9.75% plus the amount by which one-month LIBOR exceeds 2.0%. We have also agreed to make quarterly revenue based payments to the Lender in the amount of 0.2% of their consolidated revenue in accordance with GAAP, in any quarter in which our EBITDA is negative, or 0.4% of such consolidated revenue if our EBITDA is positive. We have recognized approximately $21,000 in interest expense for revenue based payments for the twelve months ended December 31, 2018, respectively. A final payment equal to 6.0% of each loan tranche will be due on the scheduled maturity date of March 1, 2022 for each loan. In addition, if we repay all or a portion of the loan prior to the applicable maturity date, we will pay the Lender a prepayment penalty fee, based on a percentage of the then outstanding principal balance, equal to 3% if the prepayment occurs during the interest-only payment period, 2% thereafter, plus the amount by which the Revenue Based Payments received prior to such prepayment did not exceed certain minimum thresholds. We recognized approximately $339,000 in interest expense for the year ended December 31, 2018.
Obligations under the Loan Agreement are secured by a first priority security interest in all of our respective assets, with the exception of intellectual property. We have agreed not to pledge or otherwise encumber our intellectual property assets, subject to certain exceptions.
The Loan Agreement includes customary affirmative and restrictive covenants, excluding any covenants to attain or maintain certain financial metrics, and also includes customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% may be applied to the outstanding loan balances (and a late payment fee of 6% of the amount due incurred), and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
In connection with the Loan Agreement, we were obligated to pay the Lender a $75,000 commitment fee.
We recognized approximately $588,000 of debt discount associated with this Loan Agreement, which is being amortized to interest expense using the effective interest method over the term of the Loan Agreement. Amortization of the debt discount associated with the Loan Agreement was approximately $111,000 for the year ended December 31, 2018 and is included in interest expense in the accompanying consolidated statements of operations.
Also in June 2018, we entered into a loan and security agreement in connection with a $2.5 million receivables financing facility with Corporate Finance, a division of Heritage Bank of Commerce (the “A/R Facility”). The A/R Facility provides for us to borrow up to 85% of our eligible accounts receivable, as defined in the A/R Facility. Interest on such borrowings accrues at the rate of the Wall Street Journal Prime Rate plus 3.0%. The lender under the A/R Facility is entitled to an annual facility fee of 1% and the initial term of the A/R Facility is two years. Obligations under the A/R Facility are secured by a first priority security interest in all of our personal property, with the exception of intellectual property, and are senior to all borrowings under the Loan Agreement pursuant to an intercreditor agreement. We have not borrowed on the A/R Facility as of December 31, 2018
The A/R Facility includes customary affirmative and restrictive covenants, including covenants to maintain an asset coverage ratio of at least 2.00 to 1.00 (subject to decrease to 1.25 to 1.00 in the event the Company is EBITDA positive for at least two quarters), that the Company’s EBITDA for any quarter shall not negatively vary by more than 30% from the Company’s financial plan and that the Borrowers’ liquidity shall be at least three times the absolute value of the Company’s EBITDA loss for the preceding three months, and also includes customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes. The Debt Financing Agreements also include customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes.
In connection with the A/R Facility, we issued Heritage Bank of Commerce warrants to purchase an aggregate of 9,720 shares of common stock (the “Heritage Warrants”), subject to a reduction in the event of early termination of the A/R Facility agreement. These warrants were recorded as debt issuance costs as well as all fees associated with securing the A/R Facility and are being amortized to interest expense over the two-years term of the A/R Facility using the straight-line method. We recognized approximately $262,000 of debt issuance costs associated with the A/R Facility, and the amortization of the debt issuance costs associated with the A/R Facility was approximately $71,000 for the twelve months ended December 31, 2018 and is included in interest expense in the accompanying consolidated statements of operations.
Note 13. Restricted Cash
In September 2018 we entered into a lease agreement for our new corporate office space in Santa Monica, California which requires us to maintain a stand-by letter of credit as a guarantee for future rent in the amount of $408,000. The amount of the letter of credit approximates its annual contract value and is fully secured by our cash. We are required to maintain the entire $408,000 stand-by letter of credit through May 2019 which is subject to annual reductions if we are not in default on our rental obligation under the lease. In addition, we have a $71,000 letter of credit required by one of our Health Plan contracts. The letter of credit is subject to renewal in February 2019 and we do not intend to renew. As of December 31, 2018, we had $408,000 of restricted cash related to the Santa Monica lease in long-term assets and $71,000 of restricted cash related to Health Plan contract in current assets.
The following table provides a reconciliation of cash, cash equivalents and restricted cash for the years ended December 31, 2018 and 2017:
(in thousands) | 2018 | 2017 | ||||||
Cash and cash equivalents | $ | 3,091 | $ | 4,779 | ||||
Restricted cash | 479 | - | ||||||
Total cash, cash equivalents and restricted cash | $ | 3,570 | $ | 4,779 | ||||
Note 14. Subsequent Events
In February 2019, we borrowed $976,000 on the A/R Facility twice during the month, of which none is outstanding as of March 19, 2019.
In February 2019, we increased the number of shares in the 2017 Plan by 552,884 shares as allowed in the 2017 Plan for annual increases to the number of shares available under the 2017 Plan.
In March 2019, we entered into an amended and restated venture loan and security agreement (as so amended and restated, the “Amended Loan Agreement”) with Horizon, which provides for up to $15.0 million in loans to us, including initial term loans in the amount of $7.5 million previously funded under the original Loan Agreement entered into in June 2018 and an additional up to $7.5 million loan in three revolving tranches of $2.5 million in availability, subject to the Company’s achievement of trailing three month billings exceeding $5.0 million, $7.0 million and $8.0 million, respectively. An initial advance of $2.5 million was funded upon the execution and delivery of the Loan Agreement, subject to repayment if the foregoing $5.0 million threshold is not reached by July 1, 2019. We concurrently entered into an amendment to the previously disclosed $2.5 million A/R Facility with Corporate Finance intended primarily to reflect the amendment and restatement of the Amended Loan Agreement.
F-25